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Abedi, Vida. M.Sc. The University of Memphis. 05/2011. Knowledge discovery 
through large-scale literature-mining of biological text-data. Major Professor: Dr. 
Mohammed Yeasin. 
The aim of this study is to develop scalable and efficient literature-mining 
framework for knowledge discovery in the field of medical and biological sciences. 
Using this scalable framework, customized disease-disease interaction network can be 
constructed. Features of the proposed network that differentiate it from existing networks 
are its 1) flexibility in the level of abstraction, 2) broad coverage, and 3) domain 
specificity. Empirical results for two neurological diseases have shown the utility of the 
proposed framework. The second goal of this study is to design and implement a bottom-
up information retrieval approach to facilitate literature-mining in the specialized field of 
medical genetics. Experimental results are being corroborated at the moment. 
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In the post-genomic era and with the advances in high-throughput technologies 
new doors have been opened to study and map genetic networks including human 
diseases [1,2,3].  Most of the new research directions focused on the genetic causes of 
diseases looking only at one or few diseases at once. It was only in 2007 that Goh K.I. et 
al., [3] took a conceptually different approach; they proposed an interaction between two 
diseases when both diseases were associated with a common gene. This idea led to 
construction of diseasome, disease-disease interaction network [3]. This higher level of 
abstraction, moving from one disease and many genes or gene-by-products to many 
diseases and their respective genes or gene-by-products, provided a new outlook to view 
genetic networks. However, the disease-disease interaction network proposed by Goh 
K.I. et al., [3] relied only on gene-disease interaction data. It was only recently that a 
combination of disease-gene information and protein-protein information [4] was used to 
enhance the quality of such network. These types of high level analysis provide insights 
into topological features and functional properties of the disease interaction network. 
However, diseases can also be connected through non-genetic features such as risk 
factors, side-effect of drugs or treatments, or signs and symptoms. Therefore constructing 
a disease network based genetic and non-genetic factors can be a valuable reference for 
clinicians and medical researchers.  
Constructing a disease interaction network at a higher level of abstraction, taking 
into account concepts such as risk factors, treatment options or symptoms, requires a 
dataset that is wide in its scope and can provide genetic, epigenetic as well as non-genetic 
2 
 
information. Literature data is the only source of knowledge with a wide extent of 
information from different sources. In addition to that literature-mining of biomedical 
text data can be implemented in a scalable framework for information retrieval purposes. 
The main goal of this study is to develop a scalable and effective literature-mining 
framework to model disease-disease interaction network through usage of associated 
factors. Distinctive features of the proposed network are the followings: 1) flexibility in 
the level of abstraction, 2) broad coverage, and 3) domain specificity.  
Flexibility in the level of abstraction: A separation between a disease and a 
symptom is sometimes ambiguous. For instance, hypertension could be considered a 
disease or a symptom. In the proposed framework, customized disease networks can be 
constructed based on the required level of abstraction. Diseases, or factors are nodes of 
the network and literature-derived evidences are edges connecting the nodes. Broad 
coverage: The semantic model to build the disease-disease interaction network is 
constructed from biological text data obtained from titles and abstracts of journal 
publications. Hence, the primary collection of the data could be from a variety of sources 
such as high-throughput experimental evidences, clinical data, or empirical observations. 
Therefore, the resulting network incorporates a wide range of information providing 
robustness to noise and to technical variations. Domain specificity: Biological text data 
tend to be noisy and one of the main reasons for this noise is the specificity of the 
terminology and the large number of abbreviations in the field. To overcome some of the 
difficulties, additional measures were taken to customize this framework for biological 
sciences. In particular a multi-gram dictionary was constructed using the controlled 
vocabulary from the Medical Subject Headings (MeSH).  
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Empirical results from two neurological diseases, Ischemic stroke and Parkinson‟s 
disease have corroborated the efficacy of the proposed framework. Additional work is in 
progress to expand the dataset and to assess the performance of this framework using a 
more comprehensive benchmarking scheme. In addition, implementation of web service 
application is currently in process.  
The second goal of this study is to develop a large scale literature-mining tool to 
facilitate information retrieval for the purpose of literature search in the field of medical 
genetics. The bottom-up approach provides an unbiased system to extract valuable 
information from biological text data, which will maximize the effectiveness of 
reviewing process for medical researchers. The key idea behind these two goals is to 
develop a large scale literature-mining tool for the purpose of knowledge discovery and 





Goal and Objectives 
 
The goal of this study is to develop large scale literature-mining  framework for the 
purpose of knowledge discovery and information retrieval in the field of medical and 
biological sciences. 
Goal I: Develop a scalable and effective literature-mining framework to model disease-
disease interaction network through usage of associated factors. 
Objectives:  
I. Develop parameter optimized latent semantic analysis framework for associated 
factors 
II. Develop a scalable approach for selection of associated factors 
III. Design and implement a database system to store the literature for efficient 
mining and access of information 
IV. Develop an optimized dictionary system for biological and medical literature 
data  
V. Assess the performance of the framework 
Goal II: Develop large scale literature-mining to facilitate information retrieval for the 
purpose of literature search in the field of medical genetics. 
Objectives:  
I. Identify potential text-mining tools in bioinformatics 
II. Design an integrated system to fuse the existing bioinformatics tools 




In the past decade, science has witnessed an explosion in OMICS-based 
technologies, such as genomics, proteomics, and pharmaco-genomics. These advances 
have generated a wave of analytical tools to tackle the complex biological networks and 
high dimensional datasets. A network in biology represents a set of nodes representing 
biochemical or chemical entities and a set of edges representing interaction between those 
entities. For instance, in a protein-protein interaction network, nodes represent proteins 
and edges could be evidence for physical interaction between proteins.  
Some researchers have looked at the robustness and dynamical properties [5] of 
these networks while others have focused on the general characteristics [3,5] of these 
complex systems in order to gain a deeper understanding. Together the results from 
studying of these complex networks furthered our knowledge to a different level of 
understanding. For instance, network analysis of disease-disease interaction (where nodes 
are disease and edges are common genes between diseases) showed that the vast majority 
of genes associated with diseases are non-essential and do not tend to encode hub 
proteins; in addition to that, genes contributing to a common disorder i) have tendency 
for their by-products to interact with each other through protein-protein interactions, ii) 
have tendency to be co-expressed, and iii) tend to share Gene Ontology terms [3].  
As a result, scientists no longer attempt to study one gene or one gene-by-product 
at a time; rather they plan to study a family of genes or even group of genes that respond 
to a given perturbation (using microarrays) at one time. This trend also promotes more 
interdisciplinary collaborations to unravel disease mechanisms and shed light on some of 
the fundamental biological questions.  
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Even though networks have been built and complex systems have been reverse-
engineered to predict systems response to perturbations, no significant attempt has been 
made to create a high level view of such complex biological systems using sources of 
information other than genetics and other high-throughput experimental data. In a 
landmark study Kwang-Il Goh et al. [3] explored whether human genetic disorders are 
related to each other by analyzing their corresponding disease genes and gene-by-
products. Interaction between genetic disorders provides a higher level of abstraction 
when compared to gene regulatory networks, or protein-protein interactomes. In the latter 
case, genes or proteins are the nodes in the network for a particular disease; in the former 
case, diseases themselves are nodes in the network. In essence, disease-disease 
interaction data provides a higher level view of the biological system. This higher level of 
abstraction facilitates translational research and is instrumental in clinical studies. This 
type of analysis can provide a valuable reference for clinicians and medical researchers. 
Disease networks constructed now are mostly based on genetic and proteomic data; but 
disease network could also be constructed based on literature data to incorporate a wider 
range of factors such as side effects and risk factors.   
In fact, generating disease-models based on literature data is a very natural and 
efficient way to better understand and summarize the current knowledge about different 
high-level systems. Identifying connecting elements between diseases can provide a 
systematic approach to identify missing links and potential associations while presenting 
new opportunities for collaborations and interdisciplinary research. A connection 
between two diseases can be formalized as risk factor, symptom, treatment option, side-
effect of drugs, or any other disease as compared to only common disease-genes. Figure 1 
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represent a pictograph representation of a disease interaction network, where connections 





Figure 1. Pictograph representation of a disease interaction network using graph 
representation. 
Light blue nodes represent diseases and dark blue nodes are associated factors. Note 
that because a disease can also be considered a risk factor to a second disease, therefore 




Developing disease interaction network 
In order to construct disease interaction networks, it is essential to identify factors 
associated with each disease independently. If factors are only genetic factors, then 
genomic data could be used; however, if factors are considered to cover a wider range 
then other type of data, such as text data, could be used. In essence, to build a high level 
view of the disease interaction network, it is essential to utilize factors at a higher level of 
granularity.  For instance, instead of specific gene names it is more reasonable to know 
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that if the disease is associated with genetic factors. Therefore, “family history” could be 
used as a potential contributing factor. Similarly, instead of carefully analyzing the 
chemical structure of interacting compounds, it would be more appropriate to use groups 
of compounds such as “inorganic compounds”, or “heterocyclic compounds”. However, 
the system should be flexible enough to incorporate new factors when significant amount 









The first step in the development of disease interaction network is the 
identification of factors that are associated to the disease. The next step is to evaluate the 
level of association of the factor to the disease. In order to accomplish the first task, 
literature-mining techniques could be used to mine the textual data in the PubMed
1
 
database and extract meaningful associations. If a disease is well documented, then it is 





expected that a large body of literature will be available to corroborate the existence of 
such associations. If a disease is not well studied, then it is expected that most of the 
factors are weakly associated to the disease with only few factors displaying a high level 
of association (see figure 2, Disease X versus Disease Y). Hence the distribution of 
association level of factors (including risk factors) will be different in the two scenarios. 
In the first case (Disease X) the dominating distribution is that of potential factors; in the 
second case (Disease Y) the two dominating distributions are the factors that are 
associated and those that are not associated with the disease. Essentially, a large body of 
evidence is gathered to corroborate the existence of any association that may exist 
between the disease and the respective factor.  
In order to evaluate the level of association of a factor to a disease, a more 
complex analysis is required. It is important to mention that factors are not independent 
of each other and if statistical tests are going to be used, it is imperative to account for 
that dependency whenever possible. Furthermore, if one could hypothesize that the 
distribution of associated factors follows a tri-modal distribution then it becomes simply 
more intuitive to measure the level of association for different factors.  
The tri-modal distribution hypothesis proposed here is based on the fact that a 
disease mechanism is well understood if it is associated with a number of contributing 
factors at a relatively high score and vice-versa. Hence, as the figure 2 demonstrates, each 
distribution can be decomposed into three distributions, hence the tri-modal distribution 
model. The weights, or degree of association of a factor to a disease, are statistical 
measure of the association evaluated using literature-mining methodologies. 
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Knowledge discovery through literature-mining 
The availability of huge textual resources provides the scientists with the chance 
to search for correlations or associations such as protein-protein interactions [6,7], and 
gene-disease associations [8,9]. However, biology and medicine are rich in terminology, 
for instance, in pathology reports and medical records, 12,000 medical abbreviations have 
been identified [10].  In addition, this large vocabulary is also dynamic and new terms 
emerge rapidly. For instance, the same object may have several names, or distinct objects 
can be identified with the same name; in the former case the names are synonyms and the 
latter case the objects are homonyms [11].  Consequently, literature-mining of biological 
and medical text becomes a very challenging task and the terms that suffer the most are 
gene and protein names [12,13]. However, even more challenging is the implementation 
of the information extraction, also known as deep parsing. 
Deep parsing is built on formal mathematical models describing how text is 
generated in the human mind (i.e. formal grammar) [11]. The most popular formal 
grammars are deterministic or probabilistic context-free grammars [13]. Grammar-based 
information extraction techniques are computationally expensive because they require the 
evaluation and ranking of several alternative ways to generate the same sentence; it is 
therefore considerably slower but potentially much more precise [11]. An alternative to 
the grammar-based methods are vector-based methods such as Latent Semantic Analysis 
method. These alternative methods rely on bag-of-word concept, and have therefore 
reduced computational complexity. In addition to that, LSA technique has the added 
advantage of extracting direct and indirect association between entities.  
In essence, since the traditional information retrieval framework, which relies on 
keyword-based approaches, cannot cope with the huge amount of information that is 
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being produced on a daily basis, scientists have focused on more sophisticated techniques 
such as text-mining [13] coupled with data-mining approaches. This shift has proved to 
be valuable in many instances. For example, titles from MEDLINE were used to make 
connections between disconnected arguments: 1) the connection between migraine and 
magnesium deficiency [14] which has been verified experimentally; 2) between 
indomethacin and Alzheimer‟s disease [14]; and finally 3) between Curcuma longa and 
retinal diseases, Crohn‟s disease and disorders related to the spinal cord [15]. Hypothesis 
generation in literature-mining relies on the fact that „chance‟ connections can emerge to 
be meaningful [13]. 
Latent Semantic Analysis (LSA) 
Latent Semantic Analysis (LSA) is a well known information retrieval technique 
which has been applied to many areas in bioinformatics. In LSA framework [16], a word-
document matrix (also known as tf-idf matrix) is commonly used to represent a collection 
of text (corpus). LSA extracts relations based on second order co-occurrence from a 
corpus, and maps them on to K-dimensional vector space. The discrete indexed words are 
projected into an eigen space by applying singular value decomposition (SVD).  
Arguably, LSA captures some semantic relations between various concepts based on 
their distance in the eigen space [17]. The most common similarity measure used to rank 
the vectors is the linear cosine similarity measure [17]. The three main steps of the LSA 
are outlined here and can be found in [16]: 
I. Creation of Term-Document matrix: The text documents are represented 
using a bag-of-words model. This representation creates a term-document 
matrix in which the rows are the words (dictionary), the columns are the 
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documents, and the individual cell contains the frequency of the term 
appearance in the particular document. Term Frequency (TF) and Inverse 
Document Frequency (IDF) are used to create the TF-IDF matrix.  
II. Singular Value Decomposition (SVD): SVD or SparseSVD (approximation 
of SVD) is performed on the TF-IDF matrix and the k largest eigen vectors are 
retained. This k-dimensional matrix (encoding matrix) captures the 
relationship among words based on first and second order statistical co-
occurrences.  
III. Information Retrieval: Information related to a query can be retrieved by 
first folding-in the query into the LSA space and then performing a similarity 
measure between the documents and the query. Cosine similarity measure is 
usually used to rank and retrieve the documents. 
Parameter Optimized Latent Semantic Analysis (POLSA) 
Even though LSA has been has been applied to many areas in bioinformatics, the 
LSA models have been based on adhoc principles. In a recent work, a systematic study 
was performed on the parameters affecting the performance of LSA to develop a 
Parameter Optimized Latent Semantic Analysis (POLSA) [18]. The various parameters 
examined were corpus content, text preprocessing, sparseness of data vectors, feature 
selection, influence of the1
st
 Eigen vector, and ranking of the encoding matrix. The 
optimized parameters should be chosen whenever possible. 
Improving the semantic meaning of POLSA framework 
Methods such as LSA have been successful in finding direct and indirect 
associations between various entities; however, these methods still use bag-of-words 
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concept; therefore, they do not take into account the order of words and hence the 
meaning of such words are often lost. Using multi keyword words would alleviate some 
of the problems of the bag-of-words model. In a multi keyword dictionary the word 
“vascular accident” (which is a synonym of “stroke”) would be differentiated from 
“accident” which could also mean car accident in a different context.  
However, it is challenging to generate such a dictionary. If all combinatorial 
words in the English dictionary are chosen, then the size of such dictionary would be 
considerably large even if one considers up-to three gram words. A larger dictionary 
implies also increased sparsity in the TF-IDF matrix. A possible solution is to construct 
the dictionary based on combinations of words that are biologically relevant for the case 
of biological text-mining. Identification of biologically relevant word combinations can 
be derived from biological ontology such as Gene Ontology
2
 (GO) or Medical Subject 
Headings (MeSH)
3
. Using a multi-keyword dictionary could in principle improve the 
accuracy of the vector-based frameworks, such as the LSA, that rely only on bag-of-
words models. 
Benchmarks: knowledge-based systems 
To evaluate any system, there is a need of ground truth or at least what is believed 
to be the current knowledge. There are a number of online resources that could be used to 
construct a ground truth in biology and medical sciences. 
                                                          
2
 www.geneontology.org  
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UpToDate: UpToDate4 is a web accessible resource for clinicians. The system 
provides information for clinical decision making. It also answers clinical questions and 
summarizes sign, symptoms, side effect of drugs and treatments. UpToDate also provides 
a list of drugs or treatment options for a wide range of diseases. The system is not freely 
available to the public.   
MedLink neurology: MedLink neurology5 is similar to UpToDate in the sense it 
provides medical support to clinicians. However, MedLink neurology is especially 
targeted to neurologists; it has more in depth information about common and also rare 
neurological diseases. The system is not available to the public and requires registration. 
However, all the information is referenced and it is possible to extract original 
publications if needed. Medical summaries are usually done by few experts in the field, 
and only when sufficient amount of evidences become available, the experts will 
reference them in their clinical summaries.  
PubMed: PubMed is a public database developed and maintained by the National 
Center for Biotechnology Information (NCBI
6
), and updated on a daily basis. Currently 
this database contains more 20 million citations for biomedical literature. Whenever an 
article has an abstract, that abstract is published through PubMed. One of the features of 
retrieving articles through PubMed is the fact that all entries are tagged using the Medical 
Subject Headings
7
 controlled vocabulary. MeSH vocabularies are used to describe the 
subject of each journal article. MeSH contains approximately 26,000 terms and is 
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 http://www.uptodate.com/index  
 
5
 http://www.medlink.com/medlinkcontent.asp  
 
6
 http://www.ncbi.nlm.nih.gov/  
 
7
 http://www.ncbi.nlm.nih.gov/mesh  
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updated annually to reflect changes in the medical field. MeSH terms are arranged 
hierarchically by subject categories and PubMed allows one to view this hierarchy and 
search the literature using the controlled vocabularies.  
Constructing ground truth using PubMed MeSH controlled vocabulary is time 
consuming but feasible. However, the use of MeSH is extremely important because 
MeSH vocabulary ensures that articles are uniformly indexed by subject, whatever the 
author's words. 
Bioinformatics tools 
i. Text-mining methods in bioinformatics 
Knowledge discovery is moving away from hypothesis-driven to data-driven 
approaches [19,20]; it is indeed increasingly difficult to sustain the deductive scientific 
method because these methods are not scalable for today‟s growing body of knowledge 
[21]. In fact, advances in technology and bioinformatics tools have significantly changed 
how we design and perform experiments and analyze the results. In the past decade, 
bioinformatics tools have also explored biological text-mining and today they are able to 
provide a faster approach to scan the literature by various means. One of the goals of this 
study is to perform an unbiased literature search using such tools as a first filtering step. 
It is clear that the expert knowledge will not be replaced by these bioinformatics tools; 
however, by using a text-mining approach, the researcher will only be required to read 
the relevant information and save a significant amount of time.  
GeneIndexer: GeneIndexer8 is an unsupervised approach that provides the user 
with a list of genes ranked for a given phenotype or disease. This tool is based on a 
                                                          
8
 http://www.computablegenomix.com/  
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Latent Semantic Analysis (LSA) approach, presenting thus direct and indirect 
associations between genes and phenotypes. The user may or may not enter a list of 
genes, which will be ranked based on the query phenotype. If a list of genes is not 
provided, the system will use all the known genes in human or mouse. This tool has great 
potential in microarray studies but also as we are using it here as a first step toward an 
unbiased literature review. 
PubMatrix: PubMatrix9 is a simple, yet powerful text-mining tool. Given two lists 
of terms (with a maximum of 100 for list 1 and 10 for list 2) this tool will count the 
number of co-occurrences and will generate a matrix. Note that the queries are sent to the 
PubMed exactly as they are listed (Gene AND Term). A link to the publications where 
this co-occurrence was observed is provided to the user as a link to PubMed. The 
advantage of using this high-throughput literature search is to speed up the search and 
also to provide an overview of the genes in the set and their relationship with respect to 
the keywords. The main weakness of this methodology is the selection of keywords. 
User-defined keyword introduces bias to the system and works against the data-driven 
knowledge discovery approach. On the other hand, integrating prior knowledge may be a 
good way to control noise and provide robustness to the system. Incorporation of prior 
knowledge has been of great value in many large scale integration studies over the past 
decade [22,23,24]. In a recent study, Steele et al., [24] reported that massive 
incorporation of prior knowledge, from literature, can significantly improve reverse-
engineering of biological systems and enhance the modeling process. The intelligent 
mining of biomedical literature, for decision making, hypothesis generation and 
knowledge discovery constitutes a formidable research challenge.  
                                                          
9
 http://pubmatrix.grc.nia.nih.gov/  
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Chilibot: Chilibot10 is software designed to read the titles and abstracts from 
PubMed database in order to identify relationships between genes, proteins or any other 
entity. The results present key information that links the two entities.  For instance, a 
sentence that contains a gene name and a disease name will be returned to the user with 
the reference to the publication. In addition to that, sentences are organized into different 
types of relationships based on linguistic analysis of the text. This tool is very useful to 
the researcher at the final stage of the analysis to speed up the review process of the 
PubMed articles. 
ii. Enrichment analysis tools 
Enrichment analysis tools
11
 are comprehensive global analysis toolboxes. They 
systematically translate a set of gene list into functional profiles. Intuitively, enrichment 
analysis tools have been mostly used for study of microarray data. An array of such tools 
have been implemented and improved over the years [review in ref. 25]. One example is 
the collection of Onto-Tools. The latter is web-accessible tool which is based on Gene 
Ontology (GO) [26]. These tools attempt to translate a list of differentially regulated 
genes into an understandable set of biological phenomena. Most of these tools, including 
Onto-Express, have one common feature: they share the same infrastructure in the sense 
that they all use Gene Ontology (GO) to group genes into categories. The main difference 
among these tools are the following: 1) statistical model; 2) visualization capabilities; 3) 
level of abstraction (some of the tools only present the lowest level of GO categories, 
when other are dynamic or present a tree view representation); 4) supported microarrays; 
5) supported input IDs; and 6) user interface.   
                                                          
10
 http://www.chilibot.net/    
 
11
 http://vortex.cs.wayne.edu/projects.htm#Onto-Express and  http://biit.cs.ut.ee/gprofiler/   
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In order to make best use of these tools and to be able to obtain meaningful 
insight from them, it is imperative to understand the structure of Gene Ontology that all 
these tools are based upon (review in ref. 27). Gene Ontology has Directed Acyclic 
Graph structure within each of the three main domains (biological process, molecular 
function, and cellular component). GO structure is not uniform in its information content; 
therefore using a simple level-based analysis would not be adequate. Different 
approaches have been taken to correct for this problem [28,29].  A second major issue, 
which is also ignored often, is the fact that over 95% of the GO annotations are 
computationally derived and are not manually curated (these are indicated as IEP 
evidence code, or inferred from expression pattern) [27]; these automations often time 
use high-throughput experiments (co-expression data can be used for this purpose). This 
fact causes a circular problem: for instance consider using gene expression data to predict 
gene function while including annotations that are derived from gene expression datasets. 
In order to avoid this problem, one should consider filtering annotations based on the 
evidence code [27]. This becomes particularly important when one wishes to 
experimentally validate a hypothesis generated by these models, especially when the 
required experiment is expensive and time consuming (for instance generating a knock 
out mouse). Finally, a tool such as Onto-Express can automatically translate a list of 







To achieve the main goals of this study, which is to develop a scalable and 
effective literature-mining framework to model disease-disease interaction network 
through usage of associated factors, Parameter Optimized LSA (POLSA) was used. In the 
first section (section A), the methodologies as well as the parameters of the system are 
described in detail. These include the dataset, parameters of POLSA, disease-disease 
interaction network model, evaluation, and web-service design and implementation. In 
order to achieve the second goal of this study, to develop a large scale literature-mining 
tool to facilitate information retrieval for the purpose of literature search in the field of 
medical genetics, integration of a number of text-mining tools was done.  Additionally, in 
the second section of this chapter (section B), a detailed description of the tool integration 
strategy for the development of large scale literature-mining is presented.  
Finally, the key idea behind these two goals is to develop a large scale literature-
mining tool for the purpose of knowledge discovery and information retrieval in medical 
and biological sciences. The ultimate aim is to examine if literature-mining techniques or 
a fusion of these techniques are capable of providing a reliable source of evidences 




Literature-mining framework to model disease-disease interaction 
network 
 
In order to develop a scalable and effective literature-mining framework to model 
disease-disease interaction network, through usage of associated factors, five different 
objectives have to be fulfilled. These objectives are detailed in the introduction section 
but can be summarized as follows: 1) Framework design: develop parameter optimized 
LSA framework for associated factors; 2) Selection step: develop a scalable approach for 
selection of associated factors; 3) Database system: design and implement a database 
system to store the literature for efficient mining and access of information; 4) 
Optimization of the system: develop an optimized dictionary system for biological and 
medical literature data; 5) Assessment of the framework: assess the performance of the 
framework by comparing the output of the system with the ground truth for two disease. 
Framework design: disease modeling using tri-modal distribution scheme  
 
A set of associated factors, including risk factors, side effects of drugs or 
treatments, are selected to generate a set of documents, where each factor is represented 
by one document. Using the LSA technique or the improved POLSA technique, it is 
possible to rank the documents based on their association to a given query, which in this 
case is a disease such as “stroke”. The highly ranked documents with respect to a disease 
are considered factors associated with that disease.  
Furthermore, the distribution of a set of associated factor with respect to a disease 
can be modeled as a tri-modal distribution: sum of three normal distributions. This is due 
to the fact that, some factors are known to be associated to the disease and these have 
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high scores; similarly some factors are known to not be associated to the diseases and 
these have negative scores; in addition, some factors may or may not be associated to the 
disease and these have low similarity scores. Using a tri-modal model it is possible to 
separate the three distributions. 
To obtain the three separate distributions from the ranked documents, Matlab‟s 
curve fitting toolbox is used. The input to this toolbox is a one-dimensional distribution 
and the resulting output is the set of parameters of three normal distributions.  In fact, the 
cosine scores, representing the association of a disease with all the factors, are used to 
generate a histogram. This histogram is imported in the curve fitting toolbox where a 
general Gaussian model is used to generate the tri-modal distribution. Goodness of fit is 
measured using an R-square score. R-square is expected to be higher for well studied 
diseases such as Ischemic Stroke as compared to Parkinson‟s disease because the well 
studied diseases tend to have a better separation between the associated and non-
associated factors.  
The parameters of the POLSA model are detailed in the following section:  
To increase the performance of the LSA, two parameters were pre-set based on a 
previous work done in our lab: 97% criteria for semantic space reduction and exclusion 
of the 1
st
 eigen value component in the projected space. 
Dataset: The set of 97 factors. PubMed database was used to download titles and 
abstracts of articles from the past twenty years using risk factors as queries to PubMed. 
Based on the results obtained by the first analysis, it was clear that only twenty years of 
literature may not be enough to capture our existing knowledge. Therefore, the time 
frame was expanded to fifty years of publications for the set of 276 factors. The set of 276 
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factors derived from MeSH. PubMed database was used to download titles and abstracts 
of articles from the past fifty years following an integrated strategy (see figure 12) to 
generate the queries that were sent to PubMed. In order to implement this framework, 
NCBI Eutilies, in particular Esearch and Efetch were utilized. Detailed about the 
selection process of these factors is presented in the following section. 
Weighting scheme: Term Frequency-Inverse Document Frequency (TF-IDF) is 
used as a weighting scheme in the LSA model. No pre-processing is performed for the 
initial analysis where the set of risk factors is limited to 97 factors. Stop word removal is 
used as a pre-processing step when the set of risk factors is 276. No stemming is 
performed in the two experimental set up.  
Query to the system: Any Medical Subject Heading could be used as query to 
the system. This will allow users to search and construct content-rich relationship 
network between diseases, risk factors, chemical compounds and more. There are over 
38,000 possible queries to the system based on the multi-gram based dictionary (as 
described in section 4) and over 19,000 keywords based on simple MeSH dictionary. 
Similarity measure: Cosine similarity measure is used as the similarity measure in this 
study. The latter is defined as the score given to a gene-document dj with respect to a 
query q by the measure of cosine of the angle between the corresponding vectors in the 
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Selection Step: risk factor identification using expert knowledge and MeSH hierarchy 
A set of 97 associated factors (see table 1 in the supplemental material) were 
identified through a systematic review of medical articles and case reports; this list was 




Table 1: Potential risk factors / contributing factors selected by medical expert 
Tobacco smoking, alcohol consumption, health education and health promotion, pregnancy 
outcome, heterosexual, homosexual, maternal influenza, chemical agents, wood dust (exposure), 
silica dust (exposure), postmenopause, lifestyle intervention, diet nutrition, stress, age gender, 
oral contraceptive (OC), depression, breast-feeding, head trauma, abdominal adiposity, 
bisphenol-A (PBA),   diethylstibestrol (DES), estradiol (E2), outdoor worker, indoor worker, 
fracture, bone mineral density (BMD), body mass index (BMI), Hormone, exposure polycyclic 
aromatic hydrocarbons, hepatitis B virus, Aflatoxin,  night shift work, cholesterol level, family 
history, morning cortisol level, Mood, hypothyroidism, hyperthyroidism, insomnia, retrovirus, 
enterovirus, volume of cerebrum, volume of hippocampus, volume of lateral ventricle, caffeine, 
motor activity assessment, Cannabis, cocaine, viral infection, bacterial infection, addiction,  air 
pollutants, volatile organic compounds,  Pesticide, calcium deficiency or calcium overdose,  
phosphorus deficiency or phosphorus overdose, magnesium deficiency or magnesium overdose, 
sodium deficiency or sodium overdose, potassium deficiency or potassium overdose, sulphur 
deficiency or sulphur overdose, chloride deficiency or chloride overdose, chromium deficiency 
or chromium overdose, copper deficiency or copper overdose, fluoride deficiency or fluoride 
overdose, iodine deficiency or iodine overdose,  iron deficiency or iron overdose,  manganese 
deficiency or manganese overdose, molybdenum deficiency or molybdenum overdose, selenium 
deficiency or selenium overdose, zinc deficiency or zinc overdose, vitamin A or Retinol, vitamin 
B1 or Thiamine, vitamin B2 or Riboflavin, vitamin B3 or Niacin, vitamin B5 or Pantothenic 
acid, vitamin B6 or Pyridoxine, vitamin B7 or Biotin, vitamin B9 or Folic acid, vitamin B12 or 
Cyanocobalamin, vitamin C or Ascorbic acid, vitamin D or Calciferol, vitamin E or Tocopherol, 
vitamin K or Phylloquinone, Asthma, Autism, Schizophrenia, HIV,  immunological disorder, 
Bipolar, Hypertension, Osteoporosis, coronary heart disease (CHD), Diabetes, Allergy, Herpes, 




Subsequently, a set of 276 MeSH were selected to construct a list of potential risk 
factors and other associated factors (see table 6). The advantages of using MeSH-based 
factors are: 1) the terms are controlled vocabulary, constituting more than 25,000 subject 
headings in an eleven-level hierarchy and 83 subheadings in the 2010 edition; 2) using an 
24 
 
up-to-dated hierarchical subject heading provides common language for communication 
and information exchange in a hierarchical manner. The list of 276 factors can be 
expanded to eventually include all the headings and sub-headings. In order to do that, it is 
essential to overcome limitations of the existing text mining tools as well as statistical 
tools at hand.  It is essential to address the systematic bias that exists for factors with 
limited number of documents; this concept is further explored in the discussion section. 
The list of 276 factors was manually revised by a medical expert. The MeSH headings for 
the construction of the corpus utilized in this study constitute two levels of hierarchy, 
giving the user different degree of granularity to analyze the results. 
Using the set of 97 factors was important to assess the system before moving to a 
large scale study in which the large amount of literature required design and construction 
of a database. However, the set of 97 factors included generic (such as “stress”) and also 
specific factors (such as “maternal influenza”) which caused an imbalance in the dataset. 
Data imbalance can be a significant source of bias in the data. Therefore, by choosing the 
factors from the MeSH hierarchy, this problem could be partially alleviated. In addition 
to that, current work is going in our lab to implement a local POLSA model and alleviate 




Database system: design and implementation of a database system to store and mine 
the literature 
The dataset for the 276 factors is downloaded from PubMed and stored in 
MySQL database. The databse construction is based on the following design (see Figure 
3).  The advantage of using a database to store the data has one key advantage. Since the 
relationship between abstract and factors is many-to-one, by saving the data into a 






Figure 3: MySQL database design. 
Three tables are used to construct the database for the MeSH-based 
factors. Factor table contains information regarding the 276 MeSH 
factors, “most recent article (year)” is used to update the entry in the 
database; FactorPMID contains information need to link the factor to 
PubMed abstracts using PMIDs (unique identifies of PubMed abstracts); 
PMIDContent contains information about each abstract. In 




Optimization of the system: development of an optimized dictionary system for 
biological and medical literature data 
For the set of 97 factors: A simple dictionary is constructed using MeSH. All the 
headings are reduced to single words. For example “Reproductive and Urinary 
Physiological Phenomena” is reduced to five words in the dictionary (Reproductive, and, 
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Urinary, Physiological, Phenomena); duplicates as well as stop words such as “and” are  
removed from the dictionary. The size of this dictionary is a slightly over 19,000.   
For the set of 276 factors derived from MeSH: A refined multi-gram dictionary is 
constructed to improve the quality of LSA model (see figure 13). The main advantage of 
using a multi-gram dictionary with LSA is to overcome some of the limitations of the 
bag-of-word model. LSA model does not take into account the order of the words and 
therefore semantic meaning is sometimes lost, especially when two or three words have a 
completely different meaning when expressed in a specific order. For instance, “vascular 
accident” is a synonym for “ischemic stroke”; however, if vascular and accident are 
considered independently then the true meaning is lost. The size of the multi-gram 
dictionary is a little over 38,000 words. 
Assessment of the framework: assess the performance of the framework 
 Ground Truth for evaluation process: for the set of 97 factors. MedLink 
Neurology is one of the most comprehensive resources, used by neurologists, for 
neurological diseases. MedLink Neurology is used as a ground truth for two of the 
diseases studied here: Parkinson disease and Ischemic stroke.  
 For the set of 276 factors derived from MeSH. A systematic literature review, 
using PubMed, is done to evaluate the existence of any association between a given 
disease and the 276 factors. Ground truth is constructed based on the information from 
PubMed using MeSH search with etiology OR complications. The information is 
meticulously read by expert and the ground truth is built accordingly.  An example of 







(("Breast Neoplasms/complications"[Mesh] OR  




 Based on the literature, each associated factor is categorized as “Established 
Factor”, “Possible Factor” or “Unknown”. The ground truth is built for two diseases: 
breast cancer and Ischemic Stroke. Breast cancer is considered a systemic disease and 
therefore associated with a larger set of factors. Ischemic stroke on the other hand is a 
relatively well studied disease with known risk factors and complications. The latter 
would provide us with a higher quality ground truth. It is imperative to mention that our 
understanding of causes and side effects of diseases are not completely accurate and 
complete, therefore it is impossible to expect the ground truth to be perfect. Improvement 
should be made on regular basis when new information becomes available.  
Validation strategy: for the set of 97 factors. The results are validated with the 
ground truth when the ground truth is based on the information from MedLink 
Neurology. Distribution of the similarity measure obtained by the LSA model is plotted 
and a gradient level of association is determined based on the shape of the distribution. 
For instance the peak representing at cosine similarity of zero represents the factors with 
potential association and the peak in the negative similarity measure is representative of 
no-association. Similarly the peak with a mean in the higher cosine measure represents 
factors associated with the disease at high, medium and low degree. This method is not 
statistically derived, yet it provides a first overview of the results. Since the number of 
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factors was limited, a statistical model or a machine learning approach would have been 
unrealistic, or would have only identified few factors as being slightly significant. 
However, using a disease model (by tri-modal distribution) allows a better 
identification of the three sets of factors: unknown association, potential association and 
established association.  The latter method is empirical and provides an intuitive 
approach to evaluate the results, especially when the number of factors is limited. A more 
sophisticated methodology is proposed when the number of factors is larger. Figure 4 






Figure 4: Illustrative example of the validation strategy for a small set of risk factor. 
The histogram represents number of factors at each similarity level when the query is 
one of the keywords in the dictionary (ex: “stroke”). Cosine similarity measure is used 
in this study, the latter ranges from -1 to +1; however similarity measure is more 
concentrated around zero especially when the dataset is large. When the set of risk 
factors is limited, a disease-model strategy is used to group the risk factors into three 
main categories: orange for high to low association level between the disease and the 
associated factor, gray for potential association and blue for no association detected. If 
a tri-model distribution is assumed for a relatively well studied disease, then this 




For the set of 276 factors derived from MeSH. Validation Strategy (work in 
progress) – Comparing ground truth to the results obtained by the system using three 
different strategies: 1) empirical method: Ground truth is compared to the results obtained 
by the system. A similarity score above 0.3 is considered strong; a similarity score above 
0 is considered possible association and a negative similarity score is indicative of 
unknown association.  2) Method based on experimental observation: Ground truth is 
compared to the results obtained by the system. Similarity scores are sorted and divided 
into four bins. The highest score will be compared to the established factors, the second 
highest scores are compared to the possible factors and the remaining two sets are 
compared to the unknown factors. This subdivision is based on the fact that given the two 
ground truths extracted from PubMed, approximately 50% of the factors were marked as 
unknown and the remaining were roughly divided into two sets, one being established 
factors and one being possible factors (see the results section). 3) Unsupervised machine 
learning method: Ground truth is compared to the results obtained by the system. 
Similarity scores are clustered into three bins using K-mean clustering algorithm (with 
K=3). The cluster with highest values is compared to the cluster with established factors, 
the cluster with average values is compared to the factors with possible associations; 





Develop large scale literature-mining to facilitate information retrieval 
for the purpose of literature search in the field of medical genetics  
In order to develop a large scale, scalable and effective literature-mining 
framework to facilitate information retrieval for the purpose of literature search in the 
field of medical genetics, three different objectives are outlined in the introduction 
section of this report and also summarized here.  1) Tool identification: Identification of a 
number of text-mining tools in bioinformatics; 2) System design: Design an integrated 
system to fuse the existing bioinformatics tools; 3) Assessment of the framework: Assess 
the integrated framework.  
Tool identification: Identification of a number of text-mining tools in bioinformatics 
In conventional top-down approach, manual literature review is the only tool used 
to search the literature in order to identify genes associated with a given disease state. In 
bottom-up approach, all the genes have initially the same probability of being among the 
associated genes. A number of tools have been selected for the bottom-up approach of 
searching the literature. These tools are presented in the order that they will be integrated 
starting with GeneIndexer.  
GeneIndexer: Input to GeneIndexer is the set of all human genes and the 
keyword used is “stroke”.  The top 800 genes (cosine score > 0.1) have been selected for 
further analysis.  
PubMatrix: Input to PubMatix is top 800 genes, selected form GeneIndexer, and 
seven keywords: stroke, cerebral ischemia, brain infarction, CVA, cerebrovascular 
accident, TIA, and transient ischemic attack. The average score is calculated for each 
gene and used a measure to select genes important for further analysis.  Since PubMatrix 
31 
 
allows a maximum of one-hundred terms and ten modifiers for each run, eight different 
requests were made and results were combined for the analysis. 
Literature search, Chilibot and Enrichment analysis: Literature review of the 
top selected genes is performed by reading articles, abstracts, case reports as well as 
using Chilibot to direct the literature search. This process was performed partly by the 
author but also by an expert in the field.   
In addition, enrichment analysis is performed on the set of genes to identify major 
biological processes and molecular functions that are shared among the genes. 
Enrichment analysis was performed using Onto-Express toolbox. This technique, as also 
described in introduction section, relies on the Gene Ontology information of the genes. 
System design: Design an integrated system to fuse the existing bioinformatics tools 
Figure 5 outlines the design of the integrated system. At the first stage, 
GeneIndexer is used; the latter ranks the genes and approximately the top 5% can be used 
for further investigation (top N genes). The identified genes can then be forwarded to a 
second text-mining tool such as PubMatrix along with a set of related keywords or 
synonyms. Using a cut-off, a smaller set of genes can be selected for further investigation 
by the researcher. The top M genes are limited and therefore possible to analyze them 
manually or with the help of additional tools such as Chilibot or enrichment analysis tools 







Figure 5: A flow chart describing the steps taken to perform a bottom-up 




Assessment of the framework: Assess the integrated framework: 
A literature review of the genetics of stroke is in progress. The presented 
framework was used to generate 90 genes that could potentially be directly or indirectly 
associated with stroke. A manual review of the gene list is in progress by two 
neurologists at UTHSC. This work will be presented at the AAN2011 conference in 






Literature-mining framework to model disease-disease interaction 
network 
Histogram representation of factors at different level of association with respect to 
a given disease was used to generate three Gaussian distributions. Figure 6 represents the 
data for Ischemic stroke while figure 7 represents Parkinson‟s disease. Risk factors and 
treatment options, as well as side-effects of therapies for Ischemic stroke are better 
understood than those of Parkinson‟s disease. The previous is reflected in three 
distributions: 1) the tri-modal distribution for Parkinson‟s disease has greater variance as 
compared to Ischemic stroke; 2) mean value of the rightmost distribution is higher in the 
case of Ischemic stroke. The higher variance in the case of Parkinson‟s disease is an 
indication of greater uncertainty in terms of the level of association of various factors to 
the disease.  
Additionally, the higher mean value for the right-most curve indicates a higher 
confidence; this is scored by cosine similarity measure on the factors identified to be 





Similarity score distribution for risk factors 
 
Figure 6: Distribution of factors for Ischemic stroke. 
Data and the tri-modal distribution fitted to the data using Matlab‟s curve fitting 
toolbox. The frequency represents number of factors at each similarity level when the 









Similarity score distribution for risk factors 
 
Figure 7: Distribution of factors for Parkinson‟s Disease. 
Data and the tri-modal distribution fitted to the data using Matlab‟s curve fitting 
toolbox. The frequency represents number of factors at each similarity level when the 




 The goal of this analysis is to identify and score association level of different 
factors with respect to a given phenotype state. Using a larger bin size, the histogram 
representation from figure 6 and 7 are plotted again in figure 8. Higher cosine values of 
factors correspond to higher level of association to the disease state. Negative or zero 
cosine values indicate that no association was found between the factors and the disease. 
Since the number of factors is limited to 97, it will be difficult to use p-value to select the 
association factors. Statistical methods used to generate p-value will only identify a very 
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small set of factors (i.e. 3-4) to be associated to the disease with high level of confidence; 
however this number is expected to be much larger. Using a larger set of factors will 






Figure 8: Similarity score distribution (dashed line) for risk factors associated with 
Ischemic Stroke and Parkinson‟s disease. 
Tri-modal distribution models are represented by solid lines (approximated from figure 




Comparison between the retrieved factors at varying levels of association and the 
common knowledge in medicine was made possible by reviewing the literature through 
MedLink. Medlink is a web resource for neurologist to access up-to-date information for 
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clinical use. The following figure (figure 9) demonstrates the level of cohesion and 






Figure 9: Venn diagram of potential risk factors identified by MedLink Neurology and 
the proposed literature-based risk factor identification framework (LRFIF) for Ischemic 
stroke and Parkinson‟s disease 
Association level; red: high; orange: medium; yellow: low; gray: potential; blue: none. 
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In the case of Ischemic stroke, most of the factors are identified by both systems; 
however there is a set of factors that have only been identified by the proposed approach. 
A systematic review of this set is included in the discussion section of this thesis. In the 
case of Parkinson‟s disease, a large number of factors have been identified by both 
systems; there are however a number of factors that are only been identified by one of the 
methods. A review of each of these factors is presented in the discussion section. 
Furthermore, a small scale disease network is constructed based on the 97 factors. To 
create this network, four diseases are queried, ALS, Breast Cancer, Ischemic stroke and 
Parkinson‟s disease (see figure 10); the resulting network demonstrate the association 





Figure 10: Disease network for ALS, IS, PD and BC. 
Factors include, risk factors other diseases, side effects, and signs and symptoms. 
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Increasing the number of risk factors by MeSH hierarchy provides a robust and 
scalable approach. At a first level, 276 factors are selected to construct the set of factors 
and a ground truth is constructed based on the information from PubMed (see Material 
and Methods). Two diseases are considered for this analysis: 1) breast cancer a systemic 
disease, associated with a larger number of factors; 2) Ischemic stroke, a well understood 
and well controlled disease with better defined factors and treatment options. Table 2 




Table 2: Number of identified factors for Breast Cancer and Ischemic Stroke. 












Number of factors 40 101 135 58 63 155 




The number of established factors is higher for stroke when compared to breast 
cancer; contrarily the number of possible factors is higher in the case of breast cancer. 
This observation is in accordance with the fact that Ischemic stroke is a better understood 
disease. Factors which have been associated with the disease based on a limited number 
of evidences are grouped in the category of “possible factors”. Factors that have accepted 
by the community to be associated to the disease are grouped in the “established factor” 
group, and the remaining of the factors are in the group of “unknown” factors. 
Simulations are still in progress; however, the ground truth which is the most time-




Develop large scale literature-mining to facilitate information retrieval 
for the purpose of literature search in the field of medical genetics  
Using a cut-off value of 0.1 cosine similarity score and the keyword “stroke”, 800 
human genes were selected using GeneIndexer software. These 800 genes were imported 
in PubMatrix with seven keywords as representative of the keyword stroke. PubMatrix 
returned the number of abstract for each search combination and the resulting matrix was 




Table 3: Partial results obtained from GeneIndexer and PubMatrix. 
 
       
 
 
To select the best threshold for PubMatix, different cut-offs were considered (see 
figure 11). A threshold of 1 indicates that on average, the gene had one retrieved abstract 
from PubMed when searched in combination with the seven keywords. A threshold of 1, 
resulted in 173 genes from the 800 genes, and a threshold of 5 reduces the gene list to 
113.  In this analysis, a threshold of 10 was considered, resulting in 90 genes from the set 












The list of 90 genes and their respective description is provided in the 
supplemental results section (see table 7). Further analysis of the reduced gene-set using 
enrichment analysis tools allows further classification of the genes using their respective 
Gene Ontology (GO) information. Top ten GO categories from the second, third, and 
fourth levels of GO hierarchy are listed in table 4. At level 2, the categories are more 
abstracts. The top ten categories in the fourth level of GO are analyzed further and 62 
genes were identified to be in at least one of the ten categories (see table 5). Analysis of 
62 genes or even 90 genes for a comprehensive literature review by an expert is more 




Table 4: Top 10 categories at level 2, 3 and 4 of Gene Ontology. 
Ten other interesting categories with respect to stroke are also listed. 
 


















The implementation of heterogeneous data integration for scientific and medical 
decision support systems, in addition to knowledge discovery processes is an ambitious 
project. Using the presented framework for the identification of associated factors, it is 
possible to build disease models and disease networks at different levels of granularity. 
The fact that many risk factors are diseases and can contribute to the dysfunction of 
important physiological pathways creates a circular dilemma but also a great opportunity. 
We have shown for instance, that Parkinson‟s disease is highly associated to a number of 
factors including immunological disorders, which itself is a disease. If one can 
corroborate that hypothesis, then PD can significantly benefit from innovative new 
treatment options that are currently being used for immunological disorders.   
These interactions can be used to build disease networks and promote 
interdisciplinary research in different fields. The idea of using risk and other associated 
factors derived from MeSH hierarchy as a feature space is unique in the sense that it 
provides potential for hypothesis generation and advances our understanding of complex 
diseases. In addition, this framework provides prior knowledge based on the current 
literature and can be used for a multimodal data integration strategy. More specifically, 
factors can be used to measure the degree of association between disease groups and 
generate new hypotheses for future research directions. De novo hypothesis generation 
can provide a novel approach on how we design experiments and select the parameters 
for the study.  
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Finally, in the second part of this study, a fusion on different text-mining tools 
was performed to provide a customized framework for the identification of genes related 
to a disease. The aim of this exercise was to assist medical researchers perform a review 
of the literature in a timely manner by using more than just one text-mining tool and 
exploit benefits of different techniques at once.   
Literature-mining framework to model disease-disease interaction 
network 
 
Modeling associated factors of phenotypic states (such as diseases) using a tri-
modal distribution can be beneficial in grouping factors and score their association levels. 
In a tri-modal distribution model, the rightmost distribution represents factors with the 
highest degree of association to the phenotypic state while the leftmost distribution 
represents the lowest degree of association. In the middle distribution, factors are slightly 
associated to the phenotypic state or disease; future research directions can be helpful in 
corroborating the existence or absence of such interactions. This type of analysis 
facilitates interdisciplinary research and brings together scientists from an array of fields. 
The main characteristic of the tri-modal distribution is the following: the greater the 
separation between the leftmost and rightmost distributions the more a disease is studied. 
Similarly, the more a disease is studied, the more bias there is in the distribution (mean 
values are farther apart from zero, or from each other) which translates into a smaller 
variance. 
These general features are observed in the comparative analysis of Ischemic 
stroke (IS) and Parkinson‟s disease (PD). Ischemic stroke is relatively better understood 
and researched disease with many of its risk factors and treatment outcomes documented. 
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This fact translates as expected in the disease model (see figure 6). In fact, the difference 
of mean values of the rightmost and leftmost distributions is higher in the case of IS than 
in the case of PD. Likewise, variance of all the three distributions in IS are lower than the 
variance of all the three distributions in PD. This is also clear from the shape of the two 
tri-modal distributions.   
Comparing the results obtained by the POLSA-association-study in Ischemic 
stroke (IS) and Parkinson‟s disease (PD) a number of factors were identified to be 
associated to the disease in either the proposed method or by the MedLink web-resources 
only. In the case of IS, six factors were only identified by the proposed method: lifestyle, 
calcium, minerals, depression, vitamin E and volume of lateral ventricle. A manual 
review of the literature is performed to find evidences for these associations.  
Lifestyle: In a comprehensive literature review by Galimanis et al., [30], 
important articles were analyzed to highlight recent advances in stroke prevention by 
identifying old and new lifestyle factors. Many lifestyle elements such as behavior, heavy 
alcohol consumption, active or passive smoking, physical activity, education and diet 
have been linked to stroke. It is possible that in each individual paper there are no direct 
references made to lifestyle choices; however, LSA-based technique captures direct and 
indirect associations. Based on the vast amount of literature reviewed on individual 
lifestyle factors, lifestyle was found to be highly linked to stroke.   
Calcium / minerals: Calcium was found to fairly associated to Ischemic stroke in 
our analysis (cosine score of 0.13). In a systematic review of 2906 papers, Catling LA et 
al., [31] showed a statistically significant inverse association between magnesium and 
cardiovascular mortality (OR 0.75 (95% CI 0.68, 0.82), P<0.001); however evidence for 
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calcium remained unclear. Further research is warranted to corroborate presence or 
absence of such association. An advantage of the proposed method is to expose the 
researcher to potential factors that might have been overlooked in the manual literature 
review. In addition, this analysis provides a faster and more efficient method to identify 
new research directions in the field. Moreover, POLSA-based association identification 
framework identified other minerals to be fairly to highly associated with stroke. Zinc, 
selenium, chloride, copper and phosphorus were fairly associated to stroke; while 
magnesium was moderately and chromium highly associated to stroke. Note that 
chromium is used in cobalt-chromium stent platforms for treatment of patients with 
coronary artery disease [32] therefore this association is naturally expected. 
Depression: To assess the association of depression to ischemic stroke, three 
keywords were selected: morning cortisol level, mood, and stress. This is important since 
depression can manifest itself through mood change, stress level or biochemical alteration 
of hormones such as cortisol. For instance, it is known that in “non-depressed people” the 
level of cortisol peaks in the morning and decreases as the day progresses. In depressed 
people, however, cortisol peaks earlier in the morning but does not decrease as is the case 
for normal people [33]. In a detailed review of the literature in 2010 [34] cortisol was 
found to significantly contribute to the incidence and intensity of anxiety and depression 
as well as stroke. In the POLSA framework, morning cortisol level, mood and stress had 
a cosine score of 0.48, 0.18 and 0.12 respectively. This level of association provides 
evidence that depression and stroke are likely to be associated through various elements 
such as hormone level, mood, or stress level. Such analysis can help direct further 
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research to better understand stroke and depression as diseases and plan preventive 
measures accordingly.  
Vitamin E: Vitamin E was also found to be fairly associated to stroke (cosine 
score of 0.12) in POLSA-based approach. In a systematic review and meta-analysis [35] 
of randomized, placebo controlled trials (published until January 2010) nine trials were 
included that investigated the effect of vitamin E on incident of stroke for a total of 
118,765 participants. The results corroborate that vitamin E increased the risk for 
hemorrhagic stroke by 22% and reduced the risk of ischemic stroke by 10%. This is a 
very important observation because our analysis was based on the literature prior to this 
review article; and based on our prediction such association was probable.  
Volume of lateral ventricle: Finally volume of lateral ventricle is also found to be 
fairly associated with stroke in our analysis (cosine score of 0.13). No strong evidence 
was found in the literature for this association; however, this may be due to the fact that 
“lateral ventricle” is directly linked to stroke [36] and articles retrieved to generate the 
document set for this factor were mostly related to “lateral ventricle” rather than volume 
of lateral ventricle. This is due to how the PubMed search returned the articles. Using 
MeSH-base factors, these types of noises are reduced to a minimum, because, if an article 
is tagged to a given MeSH category, it will most likely contain relevant information. Note 
that, some of the MeSH tags are also computationally derived; therefore this problem 
may not be completely solved.  
Similarly, in the case of PD, nine factors were identified by the proposed method 
and not by MedLink web-resource. These included the followings: immunological 
disorders; vitamin B6, B12 and K; folic acid; volume of lateral ventricle, cerebrum and 
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hippocampus; coronary heart disease and hyperthyroidism. In addition to that, five 
factors were identified by MedLink but these were only potentially link to PD in our 
analysis: Head trauma, education level, infections, estrogen in women and high level of 
fat diet. A manual review of the literature is performed to investigate the presence or lack 
of evidences for these associations.  
Immunological disorders: Immunological disorder is highly linked with PD in 
our analysis (cosine score of 0.29) but not mentioned in MedLink neurology. Decreased 
olfaction is one of the earliest non-motor signs of PD [37,38]. Additionally, the sense of 
smell has a key impact in the physiology of the immune system. Specifically, the oral-
gastrointestinal tract is the major source of immune education [39] and changes in the 
diet can alter the immunoreactivity. In fact it was shown that immunologically 
manipulated mice have changes in the diet selection [40].  Additionally immunological 
diseases are accompanied by a decrease in the sense of smell (HIV, cancer) [41,42,43]. 
These studies point to a probable link between impaired immune system and PD [38]. 
Nonetheless more directed research is strongly recommended because understanding the 
nature of PD may lay the ground for successes in the quest of delaying the progression of 
this degenerative disease. 
Vitamin B6, B12 and K: Vitamin B6, B12 and vitamin K are moderately to 
highly associated with PD in our study (cosine of 0.2, 0.21 and 0.36 respectively). 
Reviewing the literature, it was found that retrospective studies in healthy subjects 
showed no connection between intake of vitamin B12 and the risk of developing 
Parkinson's disease [44], although one study reported an association of low levels of 
vitamin B6 and Parkinson's disease [45]. However, elevated homocysteine levels in 
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patients with Parkinson's disease may accelerate neurodegeneration. But elevated levels 
of homocysteine can be treated with folate, vitamin B6, or B12 since deficiencies of these 
vitamins can lead to high homocysteine levels [46]. In addition, vitamin B6 is necessary 
for homocysteine trans-sulfuration supporting the synthesis of glutathione. The latter is 
used for the defense against oxidative stress which is also involved in PD [review in ref.  
47]. Finally, even though a lack of folate and vitamin B12, as well as elevated levels of 
homocysteine have been shown to promote neurodegeneration, there is no evidence at the 
clinical level that illustrates these compounds are involved in the specific etiology or 
pathogenesis of Parkinson's disease [47]. Therefore, more direct clinical studies are 
warranted in this field.  In addition to vitamin B, vitamin K has also been shown to be 
associated with PD in a small scale meta-analysis study [48].   
Folic acid: Folate is an essential vitamin (also known as vitamin B9) and its 
deficiency is related with an increased level of homocysteinemia. It has been shown that 
in some, an antibody is produced against folate that prevents it from properly entering the 
brain. This process has been shown to worsen certain cognitive functions of the patients 
with PD [49]. Studies are in progress to assess the impact of folate on the progression of 
PD [50]. The association of folic acid and PD in our analysis was existent but relatively 
low (cosine score of 0.1). 
Volume of lateral ventricle, cerebrum and hippocampus:  PD and brain volume 
seems to be correlated [51,52,53,54]. In fact, in a recent study [51] there was evidence of 
an association between asymmetrical lateral ventricular enlargement with PD motor 
asymmetry and progression (r=0.96, P<0.001). Further studies are needed to investigate 
the underlying mechanisms and potential for using the lateral ventricle volume 
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measurement as a marker for the progression of PD. In a different study patients with PD 
showed atrophy in the hippocampus and the prefrontal cortex [52]. Similarly, in another 
study it was found that hippocampal atrophy, prominent in PD with dementia, is 
primarily centered in the head of the hippocampus [53]. Even though it is known that 
atrophy in the hippocampus (or amygdala) is not specific to PD, [53,55] more directed 
research can facilitate differentiating patients suffering from dementia in PD and 
Alzheimer‟s disease based on non-invasive, imaging-based diagnostics. Volume of lateral 
ventricle, cerebrum and hippocampus were moderately-to-highly linked to PD in our 
study (cosine score of 0.17, 0.24 and 0.27 respectively). 
Coronary heart disease: Coronary heart disease (CHD) may be indirectly 
associated with PD through vascular dementia. Vascular dementia results from 
interrupted blood flow to the brain, often after one or a series of stroke attacks. In our 
analysis CHD was linked to PD by a cosine score of 0.12. 
Hyperthyroidism: in a retrospective study although hypothyroidism was not 
found to be more common in patients with PD, yet two major observations were made: 
men with Parkinson‟s were more likely to have abnormal thyroid laboratory tests as 
compared with controls; and 'subclinical' hyperthyroidism was found to be more 
prevalent in patients with PD [56]. Furthermore, possible association of PD and 
hypothyroidism could be through pathological intraneuronal accumulation of 
neurofilaments [57] or based on the fact that many of the symptoms of the two disorders 
are similar [58,59]. In a recent review article, where authors compared different types of 
cancer in patients with PD, it was found that thyroid cancer was reported at a higher than 
expected rate (P<0.0001) [60]. Therefore more studies are needed to shed light on the 
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underlying mechanism for this association. Furthermore it is important to note that, 
depression, an associated factor to PD (based on our analysis as well as MedLink data), is 
well known to be highly linked to thyroid dysfunction. Our analysis assigned a score of 
0.1 to the association between hyperthyroidism and PD.  
Missed associations: The relationship between head trauma and the 
development of Parkinson's disease has been an issue in neurology since James 
Parkinson's initial 1817 essay. [61,62]. As we have only reviewed publications from the 
past 20 years, it is very likely that we have overlooked the wave of publications that 
associated head trauma as a risk factor for PD (cosine score between head trauma and PD 
was 0.07). Education level was not one of our factors, but “health education and health 
promotion” was; the latter had a low but positive cosine score (0.04). Infection was 
divided into two categories: bacterial and viral infection. The score for bacterial infection 
was positive, and the score for viral infection was negative. However, since bacterial and 
viral infections are very broad categories, the amount of literature was significantly 
biased causing the cosine score to be an underestimate of the true value. This is when 
systematic bias in the dataset could cause bias in the final analysis. To alleviate this 
problem, we are working on a local-based-LSA technique, meanwhile the factors selected 
using MeSH hierarchy are more specific and therefore the bias in the dataset is expected 
to reduce. High-level of fat in the diet was not specifically selected as a factor; instead 
cholesterol was a factor in our dataset. Cholesterol was slightly linked to PD in our 
analysis (cosine score of 0.069). Estrogen in women was not specifically used in our list 
of 97 factors; instead estradiol was one of the factors and its level of association with PD 
was very low (cosine value of 0.001).  
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Parkinson‟s disease (PD) is less studied than ischemic stroke (IS) and it is clear 
from this analysis that the proportion of factors detected by both systems (POLSA-based 
analysis versus MedLink web-resource) is higher in the case of IS. Interestingly, 
associations detected only by our framework can facilitate extraction of interesting 
observations and possible trends in the field. For instance, the fact that PD could possibly 
be associated with immunological disorders is intriguing and could provide new 
prospects to prevention and possibly treatment of the disease. This also facilitates 
interdisciplinary research and enhances interaction between scientists from sub-
specialized fields.  
Improvements to the literature-mining framework to model disease-disease 
interaction network 
 
The limitations caused by manually selecting the set of factors proved to be one of 
the main drawbacks from the previous implementation of the factor identification 
network. The set of 97 factors had no hierarchical structure and was not designed to 
systematically cover a wide range of topics. In addition, it was observed that some of the 
factors were very specific (such as volume of lateral ventricle) and some very general 
(bacterial infection).  Furthermore, some of these terms were not exactly mentioned in the 
ground truth due to the level of their abstraction; hence making the comparison difficult 
and not accurate.  
To alleviate these problems, and make the system scalable to a larger set of 
factors, MeSH-based hierarchy was used and a set of 276 MeSH terms were selected to 
represent the set of factors. This selection was made by an expert in the medical field. 
The set of 276 terms were selected from the eight main categories. Selecting a larger set 
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of factors also allows factor identification in a more systematic manner; in addition, use 
of statistics and p-values for selection of relevant factors becomes realistic and feasible.   
To further improve the LSA technique, multi-gram MeSH dictionary (mono, bi 
and tri-gram dictionary) was designed and constructed; the main objective was to 
incorporate added semantic meaning and enhance the query-based selection process of 
the LSA. For example, the term “vascular accident” is equivalent to stroke, yet if the two 
keywords (“vascular” and “accident”) are considered independently the semantic 
meaning is lost in this case. We have made this observation when exploring risk factors 
of “stroke” and compared them with risk factors for “vascular accident” and other 
synonym words (Cerebral ischemia, Brain infarction, CVA, Cerebrovascular accident, 
TIA, Transient Ischemic Attack). By implementing an improved method based on multi-
gram dictionary, quality of the results is expected to be enhanced and be robust to multi-
keyword queries. However, due to the complexity of the implementation and additional 
features, simulation results are not yet completed. Nevertheless, ground truth is 
constructed for two diseases, breast cancer and ischemic stroke, based on the 276 MeSH 
terms.  
Develop large scale literature-mining to facilitate information retrieval 
for the purpose of literature search in the field of medical genetics  
 
Typically a literature review is written by an expert in the field and requires a 
great amount of time for the expert to browse and gather relevant information from the 
large amount of textual data. Ultimately, the final product is extremely useful for new 
researchers; it helps them gain a deeper understanding of the topic in a timely manner. 
However, due to the huge amount of textual data, this task is very time consuming and 
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becomes more difficult as the number of publications increases. In this study we 
proposed a semi-supervised literature review technique. The methodology has the goal of 
identifying genes that have been associated to stroke in the literature and utilizes existing 
bioinformatics tools.  The result is unbiased toward the year of publication, impact factor 
of the journal, ranking of the establishments reporting the results.  In addition, the system 
is designed to gather direct and indirect association using textual data as well as 
ontological resources (Gene Ontology). Using this approach, the focus will not only be 
on the genes but also on the biological processes and molecular functions that are 
associated with queried disease, in this case Stroke. 
As also described in the results section, using GeneIndexer, top 800 genes were 
selected. The threshold was not to discriminate genes based on low cosine score. The 
goal was to have a large pool of genes to input to a second tool (PubMatrix). Note that 
only one keyword was used for GeneIndexer, because the latter is capable of extracting 
indirect associations as well as direct associations. The large pool of genes was reduced 
to 90 genes using PubMatrix. PubMatrix relies only on direct associations, co-occurrence 
of words, to score the genes. This implies that many of the genes that were among the 
800, and were filtered out could still be important for stroke; however, the goal of this 
exercise was not to propose new hypotheses, but to gather evidences for the association 
between a given gene and the disease in a systematic manner. Hence, the methodology 
could be altered to allow gene discovery or hypothesis generation.  
The reduced gene set was analyzed using Onto-Express, an enrichment analysis 
toolbox. At the third and fourth level of GO tree, interesting categories were observed. 
For instance, coagulation, response to stimulus, and regulation of body fluid levels were 
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among the highly significant categories. In addition, other categories were identified to be 
significantly enriched such as fibrinolysis, inflammatory response, regulation of blood 
vessel size and lipid metabolic process.  Identification of these categories and the genes 
in these categories facilitate the literature review process greatly. It is time efficient and 
allows researchers to only review the relevant information. In addition, by having a 
tolerant threshold more autonomy can be given to the researcher.  Finally from the 90 
genes, 62 genes were in at least one of the highly significant GO categories. Many of 
these genes are well known to be linked to stroke.  For instance there is a large amount of 
literature associating F5, Notch3, Ace, and Nos3 to ischemic stroke as described below.  
F5: This gene encodes an essential cofactor (coagulation factor V) of the blood 
coagulation cascade. Several studies including a meta-analysis identified an association 
between this gene and stroke [see review in ref. 63,64]. 
Notch3: The mutation of this gene causes Cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). The clinical 
symptoms include recurrent strokes and transient ischemic attacks, as well as progressive 
cognitive impairment [see review in ref. 65].  
Ace: ACE produces angiotensin II and catabolises bradykinin which affect 
vascular tone, endothelial function, and smooth-muscle-cell proliferation. Several studies 
have indicated that genetic variation in this protein contributes to the risk of IS [see 
review in ref. 63,64]. 
Nos3: The glu298asp polymorphism in NOS3 gene was reported to be associated 
with IS [see review in ref. 64]. 
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A careful review of the literature based on the 90 genes, with more emphasis on 







Finally, in the post-genomic era, much focus was aimed towards utilization of 
high-throughput technologies, such as microarrays, to generate large amount of data at 
once. However, analyzing large datasets proved to be challenging and part of the research 
was focus to better understand the global view of the biological systems. In order to 
achieve that goal and shed light on some of the fundamental biological questions, 
researchers have used the large datasets to build networks; these networks helped 
scientists understand the relationship among entities and gain a deeper insight of the 
system topologies and natural laws governing the biological systems. For instance, it is 
well known today that biological networks are scale free. This has major implications; for 
example, in a protein-protein interaction network many proteins are associated with few 
proteins and only a handful of proteins are connected to a large set of proteins. This 
observation is also valid for gene-regulatory networks, in which nodes are transcription 
factors and edges are protein-DNA interactions [5].   
In essence developing a disease-disease interaction network proposed in this study 
is not a novel idea; however, the concept of using the literature to model association 
between nodes and using concepts (such as risk factors, side effects or treatment options) 
as nodes of the network is novel and can be very insightful. In a conventional network 
analysis, nodes are usually one type of entity such as genes, proteins, or even diseases, 
and edges are associates between the two entities which can be modelled differently. For 
instance, in a disease-disease interaction network, nodes are diseases and edges are 
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common genes among the disease; in a protein-protein interaction network, nodes are 
proteins and edges are genetic and/or physical association between two proteins. In the 
proposed disease-disease interaction network, nodes are factors, which could be diseases, 
side-effects of drugs, risk factors or any other biological entity (from the MeSH 
hierarchy), and edges are literature-derived associations. The flexibility of the system 
makes it practical and valuable for medical scientists. The system can be queried for any 
factor and the output returns a set of associated factors and their relative level of 
association. By querying a number of diseases it is possible to build a customized disease 
network and investigate potential relationships among different entities. Furthermore, 
since associations are modeled using literature data, it is possible to update the system 
regularly, and as the time progresses and our knowledge expands this framework 
becomes more valuable and more reliable. 
Furthermore, in the second section of this thesis we demonstrated that 
bioinformatics tools can be of great value in knowledge discovery. It is clear that the 
expert knowledge cannot be replaced by bioinformatics tools; however, by using for 
instance, a literature-mining approach, the researcher will only be required to read the 
relevant information and save a significant amount of time. For example, a biologist can 
then look for logical inconsistencies in the text. In addition, a reasonable assumption 
would be to give more weight to the latest findings, there are exceptions including errors 
or fabricated facts and an expert in the field is better at identifying these discrepancies. It 
will be unproductive not to take advantage of the array of text-mining tools that are being 
developed and offered freely to the community. However, one should always be aware of 
the limitations of these technologies. For instance as a community we agree that scientists 
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should share all useful findings. Yet some datasets are too large to include in the text-
based articles format; some facts are simply too trivial to merit a paper; isolated finding 
or negative results are often withheld from the published record. Therefore, missing 
elements in the text data are not necessarily a weakness but characteristic of the data, and 







1. Pasternak JJ: An Introduction to Human Molecular Genetics. 2nd Ed. Hoboken, 
NJ: Wiley; 2005.  
2. Broeckel U, Schork NJ. Identifying genes and genetic variation underlying 
human diseases and complex phenotypes via recombination mapping: J 
Physiol 2004, 554(Pt 1):40-45.  
3. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL: The human 
disease network. Proc Natl Acad Sci U S A 2007, 104(21):8685-8690.  
4. Xuehong Z, Ruijie Z, Yongshuai J, Peng S, Guoping T, Xing W, Hongchao L, Xia 
L: The expanded human disease network combining protein–protein 
interaction information. European Journal of Human Genetics 2011, 
doi:10.1038/ejhg.2011.30 
 
5. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK, Bumgarner R, 
Goodlett DR, Aebersold R, Hood L: Integrated genomic and proteomic analyses 
of a systematically perturbed metabolic network. Science 2001, 292(5518):929-
934.  
6. Ono T, Hishigaki H, Tanigami A, Takagi T: Automated extraction of 
information on protein–protein interactions from the biological literature. 
Bioinformatics 2001,  12:155–161 
 
7. Blaschke C, Hirschman L, Valencia A: Information extraction in molecular 
biology. Brief Bioinform 2002, 3(2):154-165. 
 
8. Hao, Y. Zhu X, Huang M, Li M: Discovering patterns to extract protein–
protein interactions from the literature. Part II. Bioinformatics 2005, 21:3294–
3300 
 
9. Chun HW, Tsuruoka Y, Kim JD, Shiba R, Nagata N, Hishiki T, Tsuji J: 
Extraction of gene-disease relations from Medline using domain dictionaries 
and machine learning. Pac Symp Biocomput 2006:4-15. 
 
10. Berman JJ: Pathology abbreviated - A long review of short terms. Archives of 
Pathology & Laboratory Medicine 2004,128(3):347-352. 
 
11. Rzhetsky A, Seringhaus M, Gerstein M: Seeking a new biology through text 
mining. Cell 2008, 134(1):9-13.  
 
12. Hirschman L, Morgan AA, Yeh AS: Rutabaga by any other name: extracting 




13. Wilbur WJ, Hazard GF, Divita G, Mork JG, Aronson AR, Browne AC: Analysis 
of biomedical text for chemical names: a comparison of three methods. Proc 
AMIA Symp 1999:176-180.  
 
14. Swanson, D, Smalheiser, N: Assessing a gap in the biomedical literature: 
magnesium deficiency and neurologic disease. Neurosci Res Commun 1994, 15: 
1–9 
 
15. Srinivasan P, Libbus B: Mining MEDLINE for implicit links between dietary 
substances and diseases. Bioinformatics 2004, 20 Suppl 1:i290-296.  
 
16. Landauer, TK, Dumais, ST: A solution to plato’s problem: the latent semantic 
analysis theory of the acquisition, induction, and representation of knowledge. 
Psychological Review 1997, 104:211-240.  
 
17. Berry MW, Browne M: Understanding Search Engines: Mathematical Modeling 
and Text Retrieval. SIAM, Philadelphia 1990.  
 
18. Yeasin M, Malempati H, Homayouni R, Sorower MS: A systematic study on 
latent semantic analysis model parameters for mining biomedical literature. 
Conference Proceedings: BMC Bioinformatics2009, 10(Suppl. 7):A6 
19. Kell DB: Metabolomics and systems biology: making sense of the soup. Curr 
Opin Microbiol 2004, 7(3):296-307.  
20. Kell DB: Theodor Bücher Lecture. Metabolomics, modelling and machine 
learning in systems biology - towards an understanding of the languages of 
cells. Delivered on 3 July 2005 at the 30th FEBS Congress and the 9th IUBMB 
conference in Budapest. FEBS J 2006, 273(5):873-894.  
 
21. Brent R, Lok L: Cell biology. A fishing buddy for hypothesis generators. 
Science 2005, 308(5721):504-506. 
 
22. Castelo R, Siebes A: Priors on network structures: biasing the search for 
Bayesian networks. Int J Approx Reason 2000, 24(1): 39-57. 
 
23. Imoto S, Higuchi T, Goto T, Tashiro K, Kuhara S, Miyano S: Combining 
microarrays and biological knowledge for estimating gene networks via 
Bayesian networks. Proc IEEE Comput Soc Bioinform Conf 2003, 2:104-113. 
24. Steele E, Tucker A, 't Hoen PA, Schuemie MJ: Literature-based priors for gene 
regulatory networks. Bioinformatics. 2009, 25(14):1768-1774. 
 
25. Khatri P, Drăghici S: Ontological analysis of gene expression data: current 
tools, limitations, and open problems. Bioinformatics 2005, 21(18):3587-3595.  
26. Khatri P, Voichita C, Kattan K, Ansari N, Khatri A, Georgescu C, Tarca AL, 
63 
 
Drăghici S: Onto-Tools: new additions and improvements in 2006. Nucleic 
Acids Res 2007, 35(Web Server issue):W206-211.  
27. Rhee SY, Wood V, Dolinski K, Draghici S: Use and misuse of the gene ontology 
annotations. Nat Rev Genet 2008, 9(7):509-515.  
 
28. Wong SL, Zhang LV, Roth FP: Discovering functional relationships: 
biochemistry versus genetics. Trends Genet 2005, 21(8):424-427.  
 
29. Myers CL, Barrett DR, Hibbs MA, Huttenhower C, Troyanskaya OG: Finding 
function: evaluation methods for functional genomic data. BMC Genomics 
2006, 7:187.  
 
30. Galimanis A, Mono ML, Arnold M, Nedeltchev K, Mattle HP: Lifestyle and 
stroke risk: a review.Curr Opin Neurol 2009, 22(1):60-8. 
 
31. Catling LA, Abubakar I, Lake IR, Swift L, Hunter PR: A systematic review of 
analytical observational studies investigating the association between 
cardiovascular disease and drinking water hardness. J Water Health 2008, 
6(4):433-42. 
32. Menown IA, Shand JA: Recent advances in cardiology. Future Cardiol 2010, 
6(1):11-7.  
 
33. Tafet GE, Idoyaga-Vargas VP, Abulafia DP, Calandria JM, Roffman SS, Chiovetta 
A, Shinitzky M: Correlation between cortisol level and serotonin uptake in 
patients with chronic stress and depression. Cogn Affect Behav Neurosci 2001, 
1(4):388-93. 
 
34. Williams GP: The role of oestrogen in the pathogenesis of obesity, type 2 
diabetes, breast cancer and prostate disease. Eur J Cancer Prev 2010, 
19(4):256-71. 
 
35. Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on 
stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010, 
341:c5702. doi: 10.1136/bmj.c5702. 
 
36. Zhang RL, Zhang ZG, Chopp M: Ischemic stroke and neurogenesis in the 
subventricular zone. Neuropharmacology 2008, 55(3):345-52.  
 
37. Benkler M, Agmon-Levin N, Shoenfeld Y: Parkinson's disease, autoimmunity, 
and olfaction. Int J Neurosci 2009, 119(12):2133-2143.  
 
38. Moscavitch SD, Szyper-Kravitz M, Shoenfeld Y: Autoimmune pathology 
accounts for common manifestations in a wide range of neuro-psychiatric 
disorders: the olfactory and immune system interrelationship. Clin Immunol 




39. Faria AM, Weiner HL: Oral tolerance. Immunol Rev 2005, 206:232-259.  
 
40. Teixeira G, Paschoal PO, de Oliveira VL, Pedruzzi MM, Campos SM, Andrade L, 
Nobrega A: Diet selection in immunologically manipulated mice. 
Immunobiology 2008, 213(1):1-12.  
 
41. Schiffman SS, Sattely-Miller EA, Taylor EL, Graham BG, Landerman LR, 
Zervakis J, Campagna LK, Cohen HJ, Blackwell S, Garst JL: Combination of 
flavor enhancement and chemosensory education improves nutritional status 
in older cancer patients. J Nutr Health Aging 2007, 11(5):439-454.  
 
42. Murphy C, Davidson TM, Jellison W, Austin S, Mathews WC, Ellison DW, 
Schlotfeldt C: Sinonasal disease and olfactory impairment in HIV disease: 
endoscopic sinus surgery and outcome measures. Laryngoscope. 2000, 110(10 
Pt 1):1707-1710.  
 
43. Zucco GM, Ingegneri G: Olfactory deficits in HIV-infected patients with and 
without AIDS dementia complex. Physiol Behav 2004, 80(5):669-674. 
 
44. Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Logroscino G, Willett WC, 
Ascherio A: Folate intake and risk of Parkinson's disease. Am J Epidemiol 
2004, 160(4):368-375.  
45. de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM: Dietary folate, 
vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 
2006, 67(2):315-318.  
46. Miller JW, Nadeau MR, Smith D, Selhub J: Vitamin B-6 deficiency vs folate 
deficiency: comparison of responses to methionine loading in rats. Am J Clin 
Nutr 1994, 59(5):1033-1039.  
 
47. Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, 
Lorenzi S, Linnebank M: Homocysteine, folate and vitamin B12 in 
neuropsychiatric diseases: review and treatment recommendations. Expert Rev 
Neurother 2009, 9(9):1393-1412.  
 
48. Iwamoto J, Matsumoto H, Takeda T: Efficacy of menatetrenone (vitamin K2) 
against non-vertebral and hip fractures in patients with neurological diseases: 
meta-analysis of three randomized, controlled trials. Clin Drug Investig 2009, 
29(7):471-479. 
49. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of 
L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin 
status. Neurology 2003, 60(7):1125-1129.  
 
50. Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. Eur J 
65 
 
Clin Pharmacol 2010, 66(2):119-125. 
 
51. Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, Li Y, Barbero X, 
Gouttard S, McKeown MJ, Mailman RB, Huang X: Asymmetrical lateral 
ventricular enlargement in Parkinson's disease. Eur J Neurol 2009, 16(4):475-
481. 
 
52. Jokinen P, Brück A, Aalto S, Forsback S, Parkkola R, Rinne JO: Impaired 
cognitive performance in Parkinson's disease is related to caudate 
dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat 
Disord 2009, 15(2):88-93. 
 
53. Bouchard TP, Malykhin N, Martin WR, Hanstock CC, Emery DJ, Fisher NJ, 
Camicioli RM: Age and dementia-associated atrophy predominates in the 
hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 
2008, 29(7):1027-1039. 
 
54. Acharya HJ, Bouchard TP, Emery DJ, Camicioli RM: Axial signs and magnetic 
resonance imaging correlates in Parkinson's disease. Can J Neurol Sci 2007, 
34(1):56-61. 
 
55. Laakso MP, Partanen K, Lehtovirta M, Hallikainen M, Hänninen T, Vainio P, 
Riekkinen P Sr, Soininen H: MRI of amygdala fails to diagnose early 
Alzheimer's disease. Neuroreport 1995, 6(17):2414-2418. 
 
56. Tandeter H, Levy A, Gutman G, Shvartzman P: Subclinical thyroid disease in 
patients with Parkinson's disease. Arch Gerontol Geriatr 2001, 33(3):295-300. 
 
57. Chinnakkaruppan A, Das S, Sarkar PK: Age related and hypothyroidism related 
changes on the stoichiometry of neurofilament subunits in the developing rat 
brain. Int J Dev Neurosci 2009, 27(3):257-261. 
 
58. García-Moreno JM, Chacón-Peña J: Hypothyroidism and Parkinson's disease 
and the issue of diagnostic confusion. Mov Disord 2003,18(9):1058-1059. 
 
59. Munhoz RP, Teive HA, Troiano AR, Hauck PR, Herdoiza Leiva MH, Graff H, 
Werneck LC: Parkinson's disease and thyroid dysfunction. Parkinsonism Relat 
Disord 2004, 10(6):381-383.  
 
60. Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C: Skin 
cancer and Parkinson's disease. Mov Disord 2010, 25(2):139-148. 
 
61. Parkinson, J: Essay on the shaking palsy. London: Whittingham and Rowland, for 
Sherwood,Neely and Jones, 1817. 
 
62. Factor SA, Sanchez-Ramos J, Weiner WJ: Trauma as an etiology of 
66 
 
parkinsonism: a historical review of the concept. Mov Disord 1988, 3(1):30-36. 
 
63. Casas JP, Hingorani AD, Bautista LE, Sharma P: Meta-analysis of genetic studies 
in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 
58,000 controls. Arch Neurol 2004, 61(11):1652-1661. 
 
64. Bersano A, Ballabio E, Bresolin N, Candelise L: Genetic polymorphisms for the 
study of multifactorial stroke. Hum Mutat 2008, 29(6):776-795. 











Figure 12:  PubMed search strategy for the 276 risk and associated factors. 
The queries to PubMed are constructed using all levels of hierarchy except the highest 
level, which is very generic. Limiters, such as start and end date are used to control the 
retrieval and also to make the system more efficient for regular updates. If the number of 
retrieved abstract is low (one-hundred) the query will expand to include more documents, 
this is done by removing the quotation marks of the higher level of the MeSH hierarchy 
(note: The number of abstract for each of the 276 factor was analyzed and based on that 
distribution a threshold of 100 was selected (data not shown)).The advantage of this is to 
remove some degree of bias (the goal is reduce the number of risk factors having fewer 
than one-hundred documents in the database). PubMed IDs are retrieved and data is 




Table 6: The 276 factors derived from MeSH. 
NO- indicates that those factors are too general and therefore not considered; however, a 
selected number of subheadings are considered and listed. In brackets: MeSH 
identification number. 
NO- Diseases [C]      
NO- Bacterial Infections and Mycoses [C01]  +     
    Bacterial Infections [C01.252]  +     
     Bacteremia [C01.252.100]  +     
     Central Nervous System Bacterial Infections [C01.252.200]  +     
     Endocarditis, Bacterial [C01.252.300]  +  
     Eye Infections, Bacterial [C01.252.354]  +     
     Fournier Gangrene [C01.252.377]     
     Gram-Negative Bacterial Infections [C01.252.400]  +     
     Gram-Positive Bacterial Infections [C01.252.410]  +     
     Pneumonia, Bacterial [C01.252.620]  +     
     Sexually Transmitted Diseases, Bacterial [C01.252.810]  +     
     Skin Diseases, Bacterial [C01.252.825]  +     
     Spirochaetales Infections [C01.252.847]  +      
    Mycoses [C01.703]  +      
    Zoonoses [C01.908]    
NO- Virus Diseases [C02]  +     
    Arbovirus Infections [C02.081]  +      
    Bronchiolitis, Viral [C02.109]      
    Central Nervous System Viral Diseases [C02.182]  +      
    DNA Virus Infections [C02.256]  +   
    Eye Infections, Viral [C02.325]  +     
    Fatigue Syndrome, Chronic [C02.330]   
NO-  Hepatitis, Viral, Human [C02.440] +   
     Hepatitis A [C02.440.420]     
     Hepatitis B [C02.440.435]  +     
     Hepatitis C [C02.440.440]  +     
     Hepatitis D [C02.440.450]  +     
     Hepatitis E [C02.440.470]   
    Opportunistic Infections [C02.597]  +    
    Pneumonia, Viral [C02.705]      
    RNA Virus Infections [C02.782]  +     
   Sexually Transmitted Diseases [C02.800]  +     
    Skin Diseases, Viral [C02.825]  +   
    Slow Virus Diseases [C02.839]  +   
    Tumor Virus Infections [C02.928]  +      
    Viremia [C02.937]      
    Zoonoses [C02.968]    
NO- Parasitic Diseases [C03]  +     
    Central Nervous System Parasitic Infections [C03.105]  +      
    Eye Infections, Parasitic [C03.300]  +    
    Helminthiasis [C03.335]  +     
    Intestinal Diseases, Parasitic [C03.432]  +   
    Liver Diseases, Parasitic [C03.518]  +     
    Lung Diseases, Parasitic [C03.582]  +    
    Mesomycetozoea Infections [C03.600]  +      
    Parasitemia [C03.695]     
    Protozoan Infections [C03.752]  +   
    Skin Diseases, Parasitic [C03.858]  +     
    Zoonoses [C03.908]    
 Neoplasms [C04]  +     
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NO- Musculoskeletal Diseases [C05]  +     
    Bone Diseases [C05.116]  +     
    Cartilage Diseases [C05.182]  +    
    Fasciitis [C05.321]  +   
    Foot Deformities [C05.330]  +    
    Hand Deformities [C05.390]  +   
    Jaw Diseases [C05.500]  +    
    Joint Diseases [C05.550]  +    
    Muscular Diseases [C05.651]  +     
    Musculoskeletal Abnormalities [C05.660]  +      
    Rheumatic Diseases [C05.799]  +      
 Digestive System Diseases [C06]  +     
 Stomatognathic Diseases [C07]  +     
 Respiratory Tract Diseases [C08]  +     
 Otorhinolaryngologic Diseases [C09]  +     
NO- Nervous System Diseases [C10]  +     
    Autoimmune Diseases of the Nervous System [C10.114]  +      
    Autonomic Nervous System Diseases [C10.177]  +      
NO-    Central Nervous System Diseases [C10.228]  +   
     Encephalomyelitis [C10.228.440]  +     
     High Pressure Neurological Syndrome [C10.228.470]     
     Movement Disorders [C10.228.662]  +     
     Spinal Cord Diseases [C10.228.854]  +   
    Chronobiology Disorders [C10.281]  +    
    Cranial Nerve Diseases [C10.292]  +    
    Demyelinating Diseases [C10.314]  +      
    Nervous System Malformations [C10.500]  +      
    Nervous System Neoplasms [C10.551]  +      
    Neurocutaneous Syndromes [C10.562]  +      
    Neurodegenerative Diseases [C10.574]  +     
    Neuromuscular Diseases [C10.668]  +   
NO-    Neurotoxicity Syndromes [C10.720]  +      
     Botulism [C10.720.150]     
     Heavy Metal Poisoning, Nervous System [C10.720.475]  +     
     MPTP Poisoning [C10.720.606]     
     Neuroleptic Malignant Syndrome [C10.720.737]   
    Sleep Disorders [C10.886]  +      
    Trauma, Nervous System [C10.900]  +    
NO- Male Urogenital Diseases [C12]  +     
    Genital Diseases, Male [C12.294]  +    
    Urogenital Abnormalities [C12.706]  +     
    Urogenital Neoplasms [C12.758]  +      
    Urologic Diseases [C12.777]  +    
     Kidney Diseases [C12.777.419]  +     
     Urinary Bladder Diseases [C12.777.829]  +     
     Urinary Tract Infections [C12.777.892]  +   
     Urolithiasis [C12.777.967]  +   
NO- Female Urogenital Diseases and Pregnancy Complications [C13]  +     
    Female Urogenital Diseases [C13.351]  +        
    Pregnancy Complications [C13.703]  +    
NO- Cardiovascular Diseases [C14]  +     
    Cardiovascular Abnormalities [C14.240]  +      
    Cardiovascular Infections [C14.260]  +         
    Vascular Diseases [C14.907]  +    
     Aortic Diseases [C14.907.109]  +     
     Arterial Occlusive Diseases [C14.907.137]  +     
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     Arteriovenous Malformations [C14.907.150]  +     
     Arteritis [C14.907.184]  +     
     Cerebrovascular Disorders [C14.907.253]  +     
     Diabetic Angiopathies [C14.907.320]  +    
     Hyperemia [C14.907.474]     
     Hypertension [C14.907.489]  +     
     Hypotension [C14.907.514]  +     
     Myocardial Ischemia [C14.907.585]  +     
     Peripheral Vascular Diseases [C14.907.617]  +   
     Vasculitis [C14.907.940]  +    
     Venous Insufficiency [C14.907.952]  +   
NO- Hemic and Lymphatic Diseases [C15]  +     
    Hematologic Diseases [C15.378]  +      
    Lymphatic Diseases [C15.604]  +    
NO- Skin and Connective Tissue Diseases [C17]  +     
    Connective Tissue Diseases [C17.300]  +      
NO- Nutritional and Metabolic Diseases [C18]  +     
NO-    Metabolic Diseases [C18.452]  +   
     Acid-Base Imbalance [C18.452.076]  +    
     Calcium Metabolism Disorders [C18.452.174]  +     
     DNA Repair-Deficiency Disorders [C18.452.284]  +     
     Glucose Metabolism Disorders [C18.452.394]  +     
     Iron Metabolism Disorders [C18.452.565]  +     
     Lipid Metabolism Disorders [C18.452.584]  +     
     Malabsorption Syndromes [C18.452.603]  +     
     Metabolic Syndrome X [C18.452.625]     
     Metabolism, Inborn Errors [C18.452.648]  +     
     Mitochondrial Diseases [C18.452.660]  +     
     Phosphorus Metabolism Disorders [C18.452.750]  +     
     Porphyrias [C18.452.811]  +     
     Proteostasis Deficiencies [C18.452.845]  +    
     Wasting Syndrome [C18.452.915]  +     
     Water-Electrolyte Imbalance [C18.452.950]  +   
NO-    Nutrition Disorders [C18.654]  +    
     Hypervitaminosis A [C18.654.301]     
     Infant Nutrition Disorders [C18.654.422]  +     
     Malnutrition [C18.654.521]  +     
     Overnutrition [C18.654.726]  +     
     Wasting Syndrome [C18.654.940]  +   
NO- Endocrine System Diseases [C19]  +     
    Adrenal Gland Diseases [C19.053]  +      
    Bone Diseases, Endocrine [C19.149]      
    Diabetes Mellitus [C19.246]  +      
    Dwarfism [C19.297]  +       
    Gonadal Disorders [C19.391]  +      
    Parathyroid Diseases [C19.642]  +      
    Pituitary Diseases [C19.700]  +          
    Thyroid Diseases [C19.874]  +      
NO- Immune System Diseases [C20]  +     
    Autoimmune Diseases [C20.111]  +    
     Addison Disease [C20.111.163]    
     Antiphospholipid Syndrome [C20.111.197]     
     Arthritis, Rheumatoid [C20.111.199]  +     
     Glomerulonephritis, IGA [C20.111.525]   
     Hepatitis, Autoimmune [C20.111.567]  
     Lupus Erythematosus, Systemic [C20.111.590]  +     
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     Purpura, Thrombocytopenic, Idiopathic [C20.111.759]     
     Thyroiditis, Autoimmune [C20.111.809]   
    Hypersensitivity [C20.543]  +      
NO- Disorders of Environmental Origin [C21]  +     
    DNA Damage [C21.111]  +      
    Occupational Diseases [C21.447]  +    
     Agricultural Workers Diseases [C21.447.080]  +    
     Dermatitis, Occupational [C21.447.270]     
     Inert Gas Narcosis [C21.447.426]     
     Persian Gulf Syndrome [C21.447.653]     
     Pneumoconiosis [C21.447.800]  +     
    Poisoning [C21.613]  +      
     Argyria [C21.613.068]     
     Arsenic Poisoning [C21.613.097]     
     Bites and Stings [C21.613.127]  +     
     Cadmium Poisoning [C21.613.165]     
     Carbon Tetrachloride Poisoning [C21.613.177]    
     Fluoride Poisoning [C21.613.380]       
     Gas Poisoning [C21.613.455]  +     
     Lead Poisoning [C21.613.589]  +     
     Manganese Poisoning [C21.613.618]     
     Mercury Poisoning [C21.613.647]  +     
     Mycotoxicosis [C21.613.680]  +     
     Neurotoxicity Syndromes [C21.613.705]  +    
     Plant Poisoning [C21.613.756]  +     
     Psychoses, Substance-Induced [C21.613.809]  +     
     Water Intoxication [C21.613.932]  
    Preconception Injuries [C21.676]      
NO-    Substance-Related Disorders [C21.739]  +      
     Alcohol-Related Disorders [C21.739.100]  +     
 Amphetamine-Related Disorders [C21.739.225]  OR Cocaine-Related 
Disorders [C21.739.300] OR Marijuana Abuse [C21.739.635] OR 
Tobacco Use Disorder [C21.739.912]   
    Wounds and Injuries [C21.866]  +    
NO- Pathological Conditions, Signs and Symptoms [C23]  +     
NO-    Pathologic Processes [C23.550]  +     
     Arrhythmias, Cardiac [C23.550.073]  +     
     Ascites [C23.550.081]     
     Azotemia [C23.550.145]     
     Dehydration [C23.550.274]    
     Emphysema [C23.550.325]  +     
     Hemorrhage [C23.550.414]  +     
     Hyperammonemia [C23.550.421]     
     Hyperbilirubinemia [C23.550.429]  +     
     Hyperuricemia [C23.550.449]     
     Hypovolemia [C23.550.455]      
     Leukocytosis [C23.550.526]     
     Menstruation Disturbances [C23.550.568]  +     
     Muscle Weakness [C23.550.695]     
     Nerve Degeneration [C23.550.737]  +     
NO-    Signs and Symptoms [C23.888]  +    
     Body Temperature Changes [C23.888.119]  +     
     Body Weight [C23.888.144]  +     
     Cardiac Output, High [C23.888.176]     
     Cardiac Output, Low [C23.888.192]     
     Chills [C23.888.208]     
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     Cyanosis [C23.888.248]     
     Eye Manifestations [C23.888.307]  +     
     Fatigue [C23.888.369]  +    
     Flushing [C23.888.388]     
     Heart Murmurs [C23.888.447]  +     
     Hot Flashes [C23.888.475]     
     Hypergammaglobulinemia [C23.888.512]     
     Intermittent Claudication [C23.888.531]     
     Mobility Limitation [C23.888.550]   
     Pain [C23.888.646]  +     
NO- Chemicals and Drugs [D]      
 Inorganic Chemicals [D01]  +       
 Organic Chemicals [D02]  +     
 Heterocyclic Compounds [D03]  +     
 Polycyclic Compounds [D04]  +       
 Macromolecular Substances [D05]  +      
 Complex Mixtures [D20]  +      
 Biomedical and Dental Materials [D25]  +     
NO- Psychiatry and Psychology [F]      
NO- Behavior and Behavior Mechanisms [F01]  +         
    Defense Mechanisms [F01.393]  +    
    Human Development [F01.525]  +     
    Personality [F01.752]  +      
NO- Psychological Phenomena and Processes [F02]  +         
NO-    Psychophysiology [F02.830]  +      
     Appetite [F02.830.071]   
     Sleep [F02.830.855]  +     
     Stress, Psychological [F02.830.900]  +   
    Religion and Psychology [F02.880]  +      
    Resilience, Psychological [F02.940]    
NO- Phenomena and Processes [G]      
NO- Metabolic Phenomena [G03]  +     
NO-    Body Composition [G03.180]  +    
     Body Fat Distribution [G03.180.134]   
NO- Immune System Phenomena [G12]  +      
    CD4-CD8 Ratio [G12.248]      
    Immunocompetence [G12.460]      
    Immunocompromised Host [G12.470]  +     
NO- Integumentary System Physiological Phenomena [G13]  +     
NO-  Skin Physiological Phenomena [G13.750]        
NO-   Skin Physiological Processes [G13.750.829]      
      Sweating [G13.750.829.855]    
   Skin Temperature [G13.750.844]   
NO- Ocular Physiological Phenomena [G14]  +       
    Refraction, Ocular [G14.760]      
    Vision Disparity [G14.930]      
    Visual Acuity [G14.940]  +     
NO- Anthropology, Education, Sociology and Social Phenomena [I]      
NO- Social Sciences [I01]  +     
    Quality of Life [I01.800]      
NO-    Sociology [I01.880]  +    
     Culture [I01.880.143]  +   
     Hierarchy, Social [I01.880.298]     
     Minority Groups [I01.880.371]     
     Social Class [I01.880.552]  +     
     Social Welfare [I01.880.787]  +   
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     Socialization [I01.880.813]     
     Socioeconomic Factors [I01.880.840]  +   
 Education [I02]  +     
 Human Activities [I03]  +      
    Exercise [I03.350]  +      
    Leisure Activities [I03.450]  +      
    Physical Fitness [I03.621]      
    Travel [I03.883]  +   
NO- Technology, Industry, Agriculture [J]      
NO- Technology, Industry, and Agriculture [J01]  +       
    Household Products [J01.516]  +     
NO- Food and Beverages [J02]  +     
NO-    Beverages [J02.200]  +      
     Alcoholic Beverages [J02.200.100]  +     
     Carbonated Beverages [J02.200.300]     
     Coffee [J02.200.325]     
     Milk [J02.200.700]  +     
     Milk Substitutes [J02.200.712]  +     
     Mineral Waters [J02.200.806]     
     Tea [J02.200.900]   
    Food [J02.500]  +    
NO- Named Groups [M]     
NO- Persons [M01]          
    Age Groups [M01.060]  +    
    Alcoholics [M01.066]      
    Athletes [M01.072]      
    Caregivers [M01.085]      
    Child, Abandoned [M01.097]      
    Child, Exceptional [M01.102]  +     
    Child of Impaired Parents [M01.106]      
    Child, Orphaned [M01.108]      
    Child, Unwanted [M01.111]      
    Consultants [M01.120]      
    Crime Victims [M01.135]  +      
    Criminals [M01.142]      
    Disabled Persons [M01.150]  +      
    Drug Users [M01.169]      
    Emigrants and Immigrants [M01.189]      
    Homebound Persons [M01.276]      
    Homeless Persons [M01.325]  +    
    Medically Uninsured [M01.385]     
    Prisoners [M01.729]      
    Refugees [M01.755]      
    Single Person [M01.785]    
    Students [M01.848]  +     
    Terminally Ill [M01.873]     
NO- Health Care [N]      
NO- Population Characteristics [N01]  +     
   Socioeconomic Factors [N01.824]     
NO- Environment and Public Health [N06]  +     







Figure 13: Multi-gram dictionary construction scheme based on MeSH. 
This scheme would guarantee construction of all possible 1, 2 and 3 keyword terms for 
the dictionary. The encryption methodology designed here would also provide a way to 
ensure the keywords are coherent and logical. For instance, the comma is used a separator 
of different terms, however, if it separates two numbers such as the case for many 
chemical names then in those cases it  will not be used as a term separator. In addition, 
the implementation is such that, it is easy to increase the multi-gram dictionary to more 
than 3 terms per keyword. Increasing the number of terms per keyword would increase 
the complexity of the search and also the dictionary size; however, with technological 
advances and increased in computational power it will be possible in near future to 







Table 7: List of 90 genes and their respective description. 
Gene Name Description 
APOH Beta-2-glycoprotein 1 precursor (Beta-2-glycoprotein I) (Apolipoprotein H) 
(Apo-H) (B2GPI) (Beta(2)GPI) (Activated protein C- binding protein) (APC 
inhibitor) (Anticardiolipin cofactor); Binds to various kinds of negatively 
charged substances such as heparin, phospholipids, and dextran sulfate. May 
prevent activation of the intrinsic blood coagulation cascade by binding to 
phospholipids on the surface of damaged cells (345 aa) 
TCN2 Transcobalamin-2 precursor (Transcobalamin II) (TCII) (TC II); Primary 
vitamin B12-binding and transport protein. Delivers cobalamin to cells (427 aa) 
TUBB1 Tubulin beta-1 chain; Tubulin is the major constituent of microtubules. It binds 
two moles of GTP, one at an exchangeable site on the beta chain and one at a 
non-exchangeable site on the alpha-chain (By similarity) (451 aa) 
LBP Lipopolysaccharide-binding protein precursor (LBP); Binds to the lipid A 
moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer 
membrane of all Gram-negative bacteria. The LBP/LPS complex seems to 
interact with the CD14 receptor (481 aa) 
PLAT Tissue-type plasminogen activator precursor (EC 3.4.21.68) (tPA) (t- PA) (t-
plasminogen activator) (Alteplase) (Reteplase) [Contains- Tissue-type 
plasminogen activator chain A; Tissue-type plasminogen activator chain B]; 
Converts the abundant, but inactive, zymogen plasminogen to plasmin by 
hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-
mediated proteolysis, it plays an important role in tissue remodeling and 
degradation, in cell migration and many other physiopathological events. Play a 
direct role in facilitating neuronal migration (562 aa) 
RETN Resistin precursor (Cysteine-rich secreted protein FIZZ3) (Adipose tissue-
specific secretory factor) (ADSF) (C/EBP-epsilon-regulated myeloid-specific 
secreted cysteine-rich protein) (Cysteine-rich secreted protein A12-alpha-like 2); 
Hormone that seems to suppress insulin ability to stimulate glucose uptake into 
adipose cells. Potentially links obesity to diabetes (108 aa) 
SULT2A1 Bile salt sulfotransferase (EC 2.8.2.14) (Hydroxysteroid Sulfotransferase) (HST) 
(Dehydroepiandrosterone sulfotransferase) (DHEA-ST) (ST2) (ST2A3); 
Catalyzes the sulfation of steroids and bile acids in the liver and adrenal glands 
(285 aa) 
HGF Hepatocyte growth factor precursor (Scatter factor) (SF) (Hepatopoeitin-A) 
[Contains- Hepatocyte growth factor alpha chain; Hepatocyte growth factor beta 
chain]; HGF is a potent mitogen for mature parenchymal hepatocyte cells, seems 
to be an hepatotrophic factor, and acts as growth factor for a broad spectrum of 
tissues and cell types. It has no detectable protease activity (728 aa) 
PON2 Serum paraoxonase/arylesterase 2 (EC 3.1.1.2) (EC 3.1.8.1) (PON 2) (Serum 
aryldialkylphosphatase 2) (A-esterase 2) (Aromatic esterase 2); Hydrolyzes the 
toxic metabolites of a variety of organophosphorus insecticides. Capable of 
hydrolyzing a broad spectrum of organophosphate substrates and a number of 
aromatic carboxylic acid esters (By similarity). Has antioxidant activity. Is not 
associated with high density lipoprotein. Prevents LDL lipid peroxidation, 
reverses the oxidation of mildly oxidized LDL, and inhibits the ability of MM-
LDL to induce monocyte chemotaxis (354 aa) 
SERPINE1 Plasminogen activator inhibitor 1 precursor (PAI-1) (Endothelial plasminogen 
activator inhibitor) (PAI); This inhibitor acts as 'bait' for tissue plasminogen 
activator, urokinase, and protein C. Its rapid interaction with TPA may function 
as a major control point in the regulation of fibrinolysis (402 aa) 
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MGP Matrix Gla-protein precursor (MGP) (Cell growth-inhibiting gene 36 protein); 
Associates with the organic matrix of bone and cartilage. Thought to act as an 
inhibitor of bone formation (103 aa) 
P11 Placental protein 11 precursor (EC 3.4.21.-) (PP11); Probable serine protease 
(369 aa) 
GNB3 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 3 (Transducin 
beta chain 3); Guanine nucleotide-binding proteins (G proteins) are involved as a 
modulator or transducer in various transmembrane signaling systems. The beta 
and gamma chains are required for the GTPase activity, for replacement of GDP 
by GTP, and for G protein- effector interaction (340 aa) 
ENSG00000111980 NG,NG-dimethylarginine dimethylaminohydrolase 2 (EC 3.5.3.18) 
(Dimethylargininase-2) (Dimethylarginine dimethylaminohydrolase 2) 
(DDAHII) (DDAH-2) (S-phase protein) (Protein G6a); Hydrolyzes N(G),N(G)-
dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which 
act as inhibitors of NOS. Has therefore a role in nitric oxide generation (285 aa) 
PPP3CC Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform (EC 
3.1.3.16) (Calmodulin-dependent calcineurin A subunit gamma isoform) 
(Calcineurin, testis-specific catalytic subunit) (CAM- PRP catalytic subunit); 
Calcium-dependent, calmodulin-stimulated protein phosphatase. This subunit 
may have a role in the calmodulin activation of calcineurin (512 aa) 
APOE Apolipoprotein E precursor (Apo-E); Mediates the binding, internalization, and 
catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo 
B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of 
hepatic tissues (317 aa) 
ACE2 Angiotensin-converting enzyme 2 precursor (EC 3.4.17.-) (ACE-related 
carboxypeptidase) (Angiotensin-converting enzyme homolog) (ACEH); 
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of 
unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able 
to hydrolyze apelin- 13 and dynorphin-13 with high efficiency. May be an 
important regulator of heart function. In case of human coronaviruses SARS and 
HCoV-NL63 infections, serve as functional receptor for the spike glycoprotein 
of both coronaviruses (805 aa) 
CRP C-reactive protein precursor [Contains- C-reactive protein(1-205)]; Displays 
several functions associated with host defense- it promotes agglutination, 
bacterial capsular swelling, phagocytosis and complement fixation through its 
calcium-dependent binding to phosphorylcholine. Can interact with DNA and 
histones and may scavenge nuclear material released from damaged circulating 
cells (224 aa) 
APCS Serum amyloid P-component precursor (SAP) (9.5S alpha-1-glycoprotein) 
[Contains- Serum amyloid P-component(1-203)]; Can interact with DNA and 
histones and may scavenge nuclear material released from damaged circulating 
cells. May also function as a calcium-dependent lectin (223 aa) 
IL6 Interleukin-6 precursor (IL-6) (B-cell stimulatory factor 2) (BSF-2) (Interferon 
beta-2) (Hybridoma growth factor) (CTL differentiation factor) (CDF); IL-6 is a 
cytokine with a wide variety of biological functions- it plays an essential role in 
the final differentiation of B-cells into Ig-secreting cells, it induces myeloma and 
plasmacytoma growth, it induces nerve cells differentiation, in hepatocytes it 
induces acute phase reactants (212 aa) 
CHAD Chondroadherin precursor (Cartilage leucine-rich protein); Promotes attachment 
of chondrocytes, fibroblasts, and osteoblasts. This binding is mediated (at least 
for chondrocytes and fibroblasts) by the integrin alpha(2)beta(1). May play an 
important role in the regulation of chondrocyte growth and proliferation (By 
similarity) (359 aa) 
TTPA Alpha-tocopherol transfer protein (Alpha-TTP); Binds alpha-tocopherol and 
enhances its transfer between separate membranes (278 aa) 
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SORL1 Sortilin-related receptor precursor (Sorting protein-related receptor containing 
LDLR class A repeats) (SorLA) (SorLA-1) (Low-density lipoprotein receptor 
relative with 11 ligand-binding repeats) (LDLR relative with 11 ligand-binding 
repeats) (LR11); Likely to be a multifunctional endocytic receptor, that may be 
implicated in the uptake of lipoproteins and of proteases. Binds LDL, the major 
cholesterol-carrying lipoprotein of plasma, and transports it into cells by 
endocytosis. Binds the receptor- associated protein (RAP). Could play a role in 
cell-cell interaction (2214 aa) 
PSMA6 Proteasome subunit alpha type 6 (EC 3.4.25.1) (Proteasome iota chain) 
(Macropain iota chain) (Multicatalytic endopeptidase complex iota chain) (27 
kDa prosomal protein) (PROS-27) (p27K); The proteasome is a multicatalytic 
proteinase complex which is characterized by its ability to cleave peptides with 
Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly 
basic pH. The proteasome has an ATP-dependent proteolytic activity (246 aa) 
ITGB3 Integrin beta-3 precursor (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD61 
antigen); Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, 
laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, 
thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-
3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, 
thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 
recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-
IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D- [...] (788 aa) 
MARS Methionyl-tRNA synthetase, cytoplasmic (EC 6.1.1.10) (Methionine--tRNA 
ligase) (MetRS) (900 aa) 
NOTCH3 Neurogenic locus notch homolog protein 3 precursor (Notch 3) [Contains- Notch 
3 extracellular truncation; Notch 3 intracellular domain]; Functions as a receptor 
for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate 
determination. Upon ligand activation through the released notch intracellular 
domain (NICD) it forms a transcriptional activator complex with RBP-J kappa 
and activates genes of the enhancer of split locus. Affects the implementation of 
differentiation, proliferation and apoptotic programs (By similarity) (2321 aa) 
CNTN3 Contactin-3 precursor (Brain-derived immunoglobulin superfamily protein 1) 
(BIG-1) (Plasmacytoma-associated neuronal glycoprotein); Contactins mediate 
cell surface interactions during nervous system development. Has some neurite 
outgrowth-promoting activity (By similarity) (1028 aa) 
SELP P-selectin precursor (Granule membrane protein 140) (GMP-140) (PADGEM) 
(Leukocyte-endothelial cell adhesion molecule 3) (LECAM3) (CD62P antigen); 
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on 
neutrophils and monocytes. Mediates the interaction of activated endothelial 
cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. 
Mediates rapid rolling of leukocyte rolling over vascular surfaces during the 
initial steps in inflammation through interaction with PSGL1 (830 aa) 
LCT Lactase-phlorizin hydrolase precursor (Lactase-glycosylceramidase) [Includes- 
Lactase (EC 3.2.1.108); Phlorizin hydrolase (EC 3.2.1.62)]; LPH splits lactose in 
the small intestine (1927 aa) 
F11 Coagulation factor XI precursor (EC 3.4.21.27) (Plasma thromboplastin 
antecedent) (PTA) (FXI) [Contains- Coagulation factor XIa heavy chain; 
Coagulation factor XIa light chain]; Factor XI triggers the middle phase of the 
intrinsic pathway of blood coagulation by activating factor IX (625 aa) 
ADD1 adducin 1 (alpha) isoform b; Membrane-cytoskeleton-associated protein that 
promotes the assembly of the spectrin-actin network. Binds to calmodulin 
(768 aa) 
GARS Glycyl-tRNA synthetase (EC 6.1.1.14) (Glycine--tRNA ligase) (GlyRS) (749 aa) 
NPC1 Niemann-Pick C1 protein precursor; Involved in the intracellular trafficking of 
cholesterol. May play a role in vesicular trafficking in glia, a process that may be 




AGTR1 Type-1 angiotensin II receptor (AT1) (AT1AR) (AT1BR); Receptor for 
angiotensin II. Mediates its action by association with G proteins that activate a 
phosphatidylinositol- calcium second messenger system (359 aa) 
ACE Angiotensin-converting enzyme, somatic isoform precursor (EC 3.4.15.1) 
(Dipeptidyl carboxypeptidase I) (Kininase II) (CD143 antigen) [Contains- 
Angiotensin-converting enzyme, somatic isoform, soluble form]; Converts 
angiotensin I to angiotensin II by release of the terminal His-Leu, this results in 
an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate 
bradykinin, a potent vasodilator. Has also a glycosidase activity which releases 
GPI-anchored proteins from the membrane by cleaving the mannose linkage in 
the GPI moiety (1306 aa) 
PTX3 Pentraxin-related protein PTX3 precursor (Pentaxin-related protein PTX3) 
(Tumor necrosis factor-inducible protein TSG-14); Plays a role in the regulation 
of innate resistance to pathogens, inflammatory reactions, possibly clearance of 
self- components and female fertility (By similarity) (381 aa) 
PF4 Platelet factor 4 precursor (PF-4) (CXCL4) (Oncostatin A) (Iroplact); Released 
during platelet aggregation. Neutralizes the anticoagulant effect of heparin 
because it binds more strongly to heparin than to the chondroitin-4-sulfate chains 
of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits 
endothelial cell proliferation, the short form is a more potent inhibitor than the 
longer form (101 aa) 
ANXA5 Annexin A5 (Annexin V) (Lipocortin V) (Endonexin II) (Calphobindin I) (CBP-
I) (Placental anticoagulant protein I) (PAP-I) (PP4) (Thromboplastin inhibitor) 
(Vascular anticoagulant-alpha) (VAC-alpha) (Anchorin CII); This protein is an 
anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-
specific complex, which is involved in the blood coagulation cascade (320 aa) 
ITGA2 Integrin alpha-2 precursor (Platelet membrane glycoprotein Ia) (GPIa) (Collagen 
receptor) (VLA-2 alpha chain) (CD49b antigen); Integrin alpha-2/beta-1 is a 
receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-
cadherin. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in 
collagen. It is responsible for adhesion of platelets and other cells to collagens, 
modulation of collagen and collagenase gene expression, force generation and 
organization of newly synthesized extracellular matrix (1181 aa) 
NOS3 Nitric-oxide synthase, endothelial (EC 1.14.13.39) (EC-NOS) (NOS type III) 
(NOSIII) (Endothelial NOS) (eNOS) (Constitutive NOS) (cNOS); Produces 
nitric oxide (NO) which is implicated in vascular smooth muscle relaxation 
through a cGMP-mediated signal transduction pathway. NO mediates vascular 
endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and 
promotes blood clotting through the activation of platelets (1203 aa) 
EEF1A2 Elongation factor 1-alpha 2 (EF-1-alpha-2) (Elongation factor 1 A-2) (eEF1A-2) 
(Statin S1); This protein promotes the GTP-dependent binding of aminoacyl-
tRNA to the A-site of ribosomes during protein biosynthesis (463 aa) 
SERPINB2 Plasminogen activator inhibitor 2 precursor (PAI-2) (Placental plasminogen 
activator inhibitor) (Monocyte Arg-serpin) (Urokinase inhibitor); Inhibits 
urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct 
from the endothelial cell- derived PAI-1 (415 aa) 
CYP7A1 Cytochrome P450 7A1 (Cholesterol 7-alpha-monooxygenase) (CYPVII) (EC 
1.14.13.17) (Cholesterol 7-alpha-hydroxylase) (504 aa) 
GPR25 Probable G-protein coupled receptor 25; Orphan receptor (361 aa) 
APLN apelin, AGTRL1 ligand (APLN), mRNA (122 aa) 
FGB Fibrinogen beta chain precursor [Contains- Fibrinopeptide B]; Fibrinogen has a 
double function- yielding monomers that polymerize into fibrin and acting as a 
79 
 
cofactor in platelet aggregation (491 aa) 
FGA Fibrinogen alpha chain precursor [Contains- Fibrinopeptide A]; Fibrinogen has a 
double function- yielding monomers that polymerize into fibrin and acting as a 
cofactor in platelet aggregation (866 aa) 
OLR1 Oxidized low-density lipoprotein receptor 1 (Ox-LDL receptor 1) (Lectin-type 
oxidized LDL receptor 1) (Lectin-like oxidized LDL receptor 1) (Lectin-like 
oxLDL receptor 1) (LOX-1) (hLOX-1) [Contains- Oxidized low-density 
lipoprotein receptor 1, soluble for; Receptor that mediates the recognition, 
internalization and degradation of oxidatively modified low density lipoprotein 
(oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis 
that induces vascular endothelial cell activation and dysfunction, resulting in 
pro-inflammatory responses, pro- oxidative conditions and a [...] (273 aa) 
TPMT Thiopurine S-methyltransferase (EC 2.1.1.67) (Thiopurine methyltransferase); 
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine 
(245 aa) 
STAB1 Stabilin-1 precursor (Fasciclin, EGF-like, laminin-type EGF-like and link 
domain-containing scavenger receptor 1) (FEEL-1) (MS-1 antigen); Acts as a 
scavenger receptor for acetylated low density lipoprotein. Binds to both Gram-
positive and Gram-negative bacteria and may play a role in defense against 
bacterial infection. When inhibited in endothelial tube formation assays, there is 
a marked decrease in cell-cell interactions, suggesting a role in angiogenesis. 
Involved in the delivery of newly synthesized CHID1/SI-CLP from the 
biosynthetic compartment to the endosomal/lysosomal system (2570 aa) 
ABO Histo-blood group ABO system transferase (NAGAT) [Includes- Glycoprotein-
fucosylgalactoside alpha-N- acetylgalactosaminyltransferase (EC 2.4.1.40) 
(Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase) (Histo-blood 
group A transferase) (A transfera; This protein is the basis of the ABO blood 
group system. The histo-blood group ABO involves three carbohydrate antigens- 
A, B, and H. A, B, and AB individuals express a glycosyltransferase activity that 
converts the H antigen to the A antigen (by addition of UDP-GalNAc) or to the 
B antigen (by addition of UDP-Gal), whereas O individu [...] (353 aa) 
LPA Apolipoprotein(a) precursor (EC 3.4.21.-) (Apo(a)) (Lp(a)); Apo(a) is the main 
constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able 
of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a 
ligand for megalin/Gp 330 (2040 aa) 
PGA3 pepsinogen 3, group I (388 aa) 
GP1BA Platelet glycoprotein Ib alpha chain precursor (Glycoprotein Ibalpha) (GP-Ib 
alpha) (GPIbA) (GPIb-alpha) (Antigen CD42b-alpha) (CD42b antigen) 
[Contains- Glycocalicin]; GP-Ib, a surface membrane protein of platelets, 
participates in the formation of platelet plugs by binding to the A1 domain of 
vWF, which is already bound to the subendothelium (627 aa) 
CD24 Signal transducer CD24 precursor; Modulates B-cell activation responses. 
Signaling could be triggered by the binding of a lectin-like ligand to the CD24 
carbohydrates, and transduced by the release of second messengers derived from 
the GPI-anchor. Promotes AG-dependent proliferation of B-cells, and prevents 
their terminal differentiation into antibody-forming cells (80 aa) 
SERPINA5 Plasma serine protease inhibitor precursor (PCI) (Protein C inhibitor) (Serpin 
A5) (Plasminogen activator inhibitor 3) (PAI-3) (PAI3) (Acrosomal serine 
protease inhibitor); Inhibits activated protein C as well as plasminogen activators 
(406 aa) 
TBCD Tubulin-specific chaperone D (Tubulin-folding cofactor D) (Beta- tubulin 
cofactor D) (tfcD) (SSD-1); Tubulin-folding protein; involved in the first step of 
the tubulin folding pathway. Modulates microtubule dynamics by capturing 
GTP-bound beta-tubulin (TUBB) (999 aa) 
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KRTAP17-1 Keratin-associated protein 17-1 (Keratin-associated protein 16.1); In the hair 
cortex, hair keratin intermediate filaments are embedded in an interfilamentous 
matrix, consisting of hair keratin-associated proteins (KRTAP), which are 
essential for the formation of a rigid and resistant hair shaft through their 
extensive disulfide bond cross-linking with abundant cysteine residues of hair 
keratins. The matrix proteins include the high- sulfur and high-glycine-tyrosine 
keratins (105 aa) 
FGG Fibrinogen gamma chain precursor; Fibrinogen has a double function- yielding 
monomers that polymerize into fibrin and acting as a cofactor in platelet 
aggregation (453 aa) 
CS Citrate synthase, mitochondrial precursor (EC 2.3.3.1) (466 aa) 
APOD Apolipoprotein D precursor (Apo-D) (ApoD); APOD occurs in the 
macromolecular complex with lecithin- cholesterol acyltransferase. It is 
probably involved in the transport and binding of bilin. Appears to be able to 
transport a variety of ligands in a number of different contexts (189 aa) 
PDE4D cAMP-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.17) (DPDE3) 
(PDE43); Regulates the levels of cAMP in the cell (809 aa) 
GPT Alanine aminotransferase 1 (EC 2.6.1.2) (ALT1) (Glutamic--pyruvic 
transaminase 1) (GPT 1) (Glutamic--alanine transaminase 1); Participates in 
cellular nitrogen metabolism and also in liver gluconeogenesis starting with 
precursors transported from skeletal muscles (496 aa) 
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase (EC 3.1.4.35) (CGB-PDE) 
(cGMP-binding cGMP-specific phosphodiesterase); Plays a role in signal 
transduction by regulating the intracellular concentration of cyclic nucleotides. 
This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'- GMP 
(875 aa) 
PC Pyruvate carboxylase, mitochondrial precursor (EC 6.4.1.1) (Pyruvic 
carboxylase) (PCB); Pyruvate carboxylase catalyzes a 2-step reaction, involving 
the ATP-dependent carboxylation of the covalently attached biotin in the first 
step and the transfer of the carboxyl group to pyruvate in the second. Catalyzes 
in a tissue specific manner, the initial reactions of glucose (liver, kidney) and 
lipid (adipose tissue, liver, brain) synthesis from pyruvate (1178 aa) 
HP Haptoglobin precursor [Contains- Haptoglobin alpha chain; Haptoglobin beta 
chain]; Haptoglobin combines with free plasma hemoglobin, preventing loss of 
iron through the kidneys and protecting the kidneys from damage by 
hemoglobin, while making the hemoglobin accessible to degradative enzymes 
(405 aa) 
ADD3 Gamma-adducin (Adducin-like protein 70); Membrane-cytoskeleton-associated 
protein that promotes the assembly of the spectrin-actin network. Binds to 
calmodulin (706 aa) 
F5 Coagulation factor V precursor (Activated protein C cofactor) [Contains- 
Coagulation factor V heavy chain; Coagulation factor V light chain]; Central 
regulator of hemostasis. It serves as a critical cofactor for the prothrombinase 
activity of factor Xa that results in the activation of prothrombin to thrombin 
(2230 aa) 
MT-ND1 NADH-ubiquinone oxidoreductase chain 1 (EC 1.6.5.3) (NADH dehydrogenase 
subunit 1); Core subunit of the mitochondrial membrane respiratory chain 
NADH dehydrogenase (Complex I) that is believed to belong to the minimal 
assembly required for catalysis. Complex I functions in the transfer of electrons 
from NADH to the respiratory chain. The immediate electron acceptor for the 
enzyme is believed to be ubiquinone (By similarity) (318 aa) 
MT-ND4 NADH-ubiquinone oxidoreductase chain 4 (EC 1.6.5.3) (NADH dehydrogenase 
subunit 4); Core subunit of the mitochondrial membrane respiratory chain 
NADH dehydrogenase (Complex I) that is believed to belong to the minimal 
assembly required for catalysis. Complex I functions in the transfer of electrons 
from NADH to the respiratory chain. The immediate electron acceptor for the 
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enzyme is believed to be ubiquinone (By similarity) (459 aa) 
FLG Filaggrin; Aggregates keratin intermediate filaments and promotes disulfide-
bond formation among the intermediate filaments during terminal differentiation 
of mammalian epidermis (4061 aa) 
MMP9 Matrix metalloproteinase-9 precursor (EC 3.4.24.35) (MMP-9) (92 kDa type IV 
collagenase) (92 kDa gelatinase) (Gelatinase B) (GELB) [Contains- 67 kDa 
matrix metalloproteinase-9; 82 kDa matrix metalloproteinase-9]; May play an 
essential role in local proteolysis of the extracellular matrix and in leukocyte 
migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a 
Gly-|-Leu bond (707 aa) 
LCN2 Neutrophil gelatinase-associated lipocalin precursor (NGAL) (p25) (25 kDa 
alpha-2-microglobulin-related subunit of MMP-9) (Lipocalin-2) (Oncogene 
24p3); Transport of small lipophilic substances (Potential) (200 aa) 
ALOX5 Arachidonate 5-lipoxygenase (EC 1.13.11.34) (5-lipoxygenase) (5-LO) (674 aa) 
F7 Coagulation factor VII precursor (EC 3.4.21.21) (Serum prothrombin conversion 
accelerator) (SPCA) (Proconvertin) (Eptacog alfa) [Contains- Factor VII light 
chain; Factor VII heavy chain]; Initiates the extrinsic pathway of blood 
coagulation. Serine protease that circulates in the blood in a zymogen form. 
Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or 
thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, 
factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor 
VIIa will also convert factor IX to factor I [...] (466 aa) 
TNF Tumor necrosis factor precursor (TNF-alpha) (Tumor necrosis factor ligand 
superfamily member 2) (TNF-a) (Cachectin) [Contains- Tumor necrosis factor, 
membrane form; Tumor necrosis factor, soluble form]; Cytokine that binds to 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by 
macrophages and can induce cell death of certain tumor cell lines. It is potent 
pyrogen causing fever by direct action or by stimulation of interleukin-1 
secretion and is implicated in the induction of cachexia, Under certain conditions 
it can stimulate cell proliferation and induce cell differentiation (233 aa) 
MTHFR Methylenetetrahydrofolate reductase (EC 1.5.1.20); Catalyzes the conversion of 
5,10- methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co- substrate for 
homocysteine remethylation to methionine (697 aa) 
CST3 Cystatin-C precursor (Cystatin-3) (Neuroendocrine basic polypeptide) (Gamma-
trace) (Post-gamma-globulin); As an inhibitor of cysteine proteinases, this 
protein is thought to serve an important physiological role as a local regulator of 
this enzyme activity (146 aa) 
GK Glycerol kinase (EC 2.7.1.30) (ATP-glycerol 3-phosphotransferase) 
(Glycerokinase) (GK); Key enzyme in the regulation of glycerol uptake and 
metabolism (553 aa) 
KL Klotho precursor (EC 3.2.1.31) [Contains- Klotho peptide]; May have weak 
glycosidase activity towards glucuronylated steroids. However, it lacks essential 
active site Glu residues at positions 239 and 872, suggesting it may be inactive 
as a glycosidase in vivo. May be involved in the regulation of calcium and 
phosphorus homeostasis by inhibiting the synthesis of active vitamin D (By 
similarity) (1012 aa) 
EPHX2 Epoxide hydrolase 2 (EC 3.3.2.10) (Soluble epoxide hydrolase) (SEH) (Epoxide 
hydratase) (Cytosolic epoxide hydrolase) (CEH); Acts on epoxides (alkene 
oxides, oxiranes) and arene oxides. Plays a role in xenobiotic metabolism by 
degrading potentially toxic epoxides. Also determines steady-state levels of 
physiological mediators. Has low phosphatase activity (555 aa) 
82 
 
ALOX5AP Arachidonate 5-lipoxygenase-activating protein (FLAP) (MK-886-binding 
protein); Seems to be required for the activation of 5-LO (5- lipoxygenase). 
Could play an essential role in the transfer of arachidonic acid to 5-LO. Binds to 
MK-886, a compound that blocks the biosynthesis of leukotrienes (161 aa) 
TARS Threonyl-tRNA synthetase, cytoplasmic (EC 6.1.1.3) (Threonine--tRNA ligase) 
(ThrRS) (723 aa) 
ITGA2B Integrin alpha-IIb precursor (Platelet membrane glycoprotein IIb) (GPalpha IIb) 
(GPIIb) (CD41 antigen) [Contains- Integrin alpha-IIb heavy chain; Integrin 
alpha-IIb light chain]; Integrin alpha-IIb/beta-3 is a receptor for fibronectin, 
fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It 
recognizes the sequence R-G-D in a wide array of ligands. It recognizes the 
sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. 
Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet 
interaction through binding of soluble fibrinogen. This step leads [...] (1039 aa) 
F2 Prothrombin precursor (EC 3.4.21.5) (Coagulation factor II) [Contains- 
Activation peptide fragment 1; Activation peptide fragment 2; Thrombin light 
chain; Thrombin heavy chain]; Thrombin, which cleaves bonds after Arg and 
Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in 
complex with thrombomodulin, protein C. Functions in blood homeostasis, 
inflammation and wound healing (622 aa) 
 
